# Heart failure > Mediated Wiki article. Canonical URL: https://mediated.wiki/source/Heart_failure > Markdown URL: https://mediated.wiki/source/Heart_failure.md > Source: https://en.wikipedia.org/wiki/Heart_failure > Source revision: 1352877599 > License: Creative Commons Attribution-ShareAlike 4.0 International (https://creativecommons.org/licenses/by-sa/4.0/) Failure of the heart to provide sufficient blood flow Not to be confused with [Cardiac arrest](/source/Cardiac_arrest), [Heart attack](/source/Heart_attack), or [Heart block](/source/Heart_block). Medical condition Heart failure Other names Congestive heart failure (CHF), congestive cardiac failure (CCF)[1][2] A man with congestive heart failure and marked jugular venous distension. External jugular vein marked by an arrow. Specialty Cardiology Symptoms Shortness of breath, exhaustion, swollen legs[3] Complications Cardiac arrest Duration Lifetime Causes Heart attack, high blood pressure, abnormal heart rhythm, excessive alcohol use, infection, heart damage[4] Risk factors Smoking, sedentary lifestyle, obesity, exposure to second-hand smoke[5] Diagnostic method Echocardiogram[6] Differential diagnosis Kidney failure, thyroid disease, liver disease, anemia, obesity[7] Medication Diuretics, cardiac medications[4][6] Frequency 40 million (2015),[8] 1–2% of adults (developed countries)[6][9] Deaths 35% risk of death in the first year[10] **Heart failure** (**HF**), also known as **congestive heart failure** (**CHF**), is a [syndrome](/source/Syndrome) caused by an impairment in the [heart](/source/Heart)'s ability to [fill with and pump](/source/Cardiac_cycle) [blood](/source/Blood). Although symptoms vary based on which side of the heart is affected, HF typically presents with [shortness of breath](/source/Shortness_of_breath), [excessive fatigue](/source/Fatigue_(medical)), and bilateral [leg swelling](/source/Peripheral_edema).[3] The severity of the heart failure is mainly decided based on [ejection fraction](/source/Ejection_fraction) and also measured by the severity of symptoms.[11][7] Other conditions that have symptoms similar to heart failure include [obesity](/source/Obesity), [kidney failure](/source/Kidney_failure), [liver disease](/source/Liver_disease), [anemia](/source/Anemia), and [thyroid disease](/source/Thyroid_disease).[7] Common causes of heart failure include [coronary artery disease](/source/Coronary_artery_disease), [heart attack](/source/Heart_attack), [high blood pressure](/source/Hypertension), [atrial fibrillation](/source/Atrial_fibrillation), [valvular heart disease](/source/Valvular_heart_disease), [excessive alcohol consumption](/source/Alcohol_use_disorder), [infection](/source/Infection), and [cardiomyopathy](/source/Cardiomyopathy).[4][6] These cause heart failure by altering the structure or the function of the heart or in some cases both.[6] There are different types of heart failure: [right-sided heart failure](/source/Right-sided_heart_failure), which affects the [right heart](/source/Right_heart), [left-sided heart failure](/source/Left-sided_heart_failure), which affects the [left heart](/source/Left_heart), and biventricular heart failure, which affects both sides of the heart.[12] Left-sided heart failure may be present with a [reduced ejection fraction](/source/Heart_failure_with_reduced_ejection_fraction) or with a [preserved ejection fraction](/source/Heart_failure_with_preserved_ejection_fraction).[10] Heart failure is not the same as [cardiac arrest](/source/Cardiac_arrest), in which blood flow stops completely due to the failure of the heart to pump.[13][14] Diagnosis is based on symptoms, physical findings, and [echocardiography](/source/Echocardiography).[6] [Blood tests](/source/Blood_test), and a [chest X-ray](/source/Chest_radiography) may be useful to determine the underlying cause.[15] Treatment depends on severity and case.[16] For people with chronic, stable, or mild heart failure, treatment usually consists of lifestyle changes, such as [not smoking](/source/Smoking_cessation), [physical exercise](/source/Physical_exercise), and dietary changes, as well as medications.[17][18][19] In heart failure due to left ventricular dysfunction, [angiotensin-converting-enzyme inhibitors](/source/Angiotensin-converting-enzyme_inhibitor), [angiotensin II receptor blockers](/source/Angiotensin_II_receptor_blocker) (ARBs), or [angiotensin receptor-neprilysin inhibitors](/source/Sacubitril%2Fvalsartan), along with [beta blockers](/source/Beta_blockers), [mineralocorticoid receptor antagonists](/source/Mineralocorticoid_receptor_antagonist) and [SGLT2 inhibitors](/source/SGLT2_inhibitor) are recommended.[6] [Diuretics](/source/Diuretics) may also be prescribed to prevent fluid retention and the resulting shortness of breath.[20] Depending on the case, an implanted device such as a [pacemaker](/source/Artificial_cardiac_pacemaker) or [implantable cardiac defibrillator](/source/Implantable_cardiac_defibrillator) may sometimes be recommended.[16] In some moderate or more severe cases, [cardiac resynchronization therapy](/source/Cardiac_resynchronization_therapy) (CRT)[21] or [cardiac contractility modulation](/source/Cardiac_contractility_modulation) may be beneficial.[22] In severe disease that persists despite all other measures, a cardiac assist device [ventricular assist device](/source/Ventricular_assist_device), or, occasionally, [heart transplantation](/source/Heart_transplantation) may be recommended.[20] Heart failure is a common, costly, and potentially fatal condition,[23] and is the leading cause of hospitalization and readmission in older adults.[24][25] Heart failure often leads to more drastic health impairments than the failure of other, similarly complex organs such as the kidneys or liver.[26] In 2015, it affected about 40 million people worldwide.[8] Overall, heart failure affects about 2% of adults,[23] and more than 10% of those over the age of 70.[6] Rates are predicted to increase.[23] The risk of death in the first year after diagnosis is about 35%, while the risk of death in the second year is less than 10% in those still alive.[10] The risk of death is comparable to that of some cancers.[10] In the United Kingdom, the disease is the reason for 5% of emergency hospital admissions.[10] Heart failure has been known since ancient times in [Egypt](/source/Ancient_Egypt); it is mentioned in the [Ebers Papyrus](/source/Ebers_Papyrus) around 1550 BCE.[27] ## Definition The term "cardiovascular insufficiency" is sometimes used when the heart does not function effectively as a pump and fails to circulate enough blood through the [circulatory system](/source/Circulatory_system) to meet the body's needs. This generally leads to the syndrome of heart failure, a combination of [signs and symptoms](/source/Signs_and_symptoms)[6]: 3612[3] when the heart functions poorly as a pump. This leads to high filling pressure in the left atrium with fluid accumulation and water retention. Most of the visible signs of heart failure are the result of this fluid accumulation ([edema](/source/Edema)) and the adjective [congestion](https://en.wiktionary.org/wiki/congestion#Noun) is added to the definition of heart failure. Impaired ejection can lead to inadequate blood flow to the body tissues, resulting in [ischemia](/source/Ischemia).[28][29] ## Signs and symptoms Signs and symptoms of severe heart failure Congestive heart failure is a [pathophysiological](/source/Pathophysiological) condition in which the [heart's output](/source/Cardiac_output) is insufficient to meet the needs of the body and lungs.[10] The term "congestive heart failure" is often used because one of the most common symptoms is [congestion](https://en.wiktionary.org/wiki/congestion#Noun) or fluid accumulation in the tissues and veins of the lungs or other parts of a person's body.[10] Congestion manifests itself particularly in the form of [fluid accumulation and swelling (edema)](/source/Edema), in the form of [peripheral edema](/source/Peripheral_edema) (causing swollen limbs and feet) and [pulmonary edema](/source/Pulmonary_edema) (causing difficulty breathing) and [ascites](/source/Ascites) (swollen abdomen).[29] [Pulse pressure](/source/Pulse_pressure), which is the difference between the systolic ("top number") and diastolic ("bottom number") blood pressures, is often low/narrow (i.e. 25% or less of the level of the systolic) in people with heart failure, and this can be an early warning sign.[30] Symptoms of heart failure are traditionally divided into left-sided and right-sided because the left and right ventricles supply different parts of the circulation. In biventricular heart failure, both sides of the heart are affected. Left-sided heart failure is the more common.[31] ### Left-sided failure The left side of the heart takes oxygen-rich blood from the lungs and pumps it to the rest of the [circulatory system](/source/Circulatory_system) in the body (except for the [pulmonary circulation](/source/Pulmonary_circulation)). Failure of the left side of the heart causes blood to back up into the lungs, causing breathing difficulties and fatigue due to an insufficient supply of oxygenated blood. Common respiratory signs include [increased respiratory rate](/source/Tachypnea) and labored breathing (nonspecific signs of shortness of breath). [Rales](/source/Rales) or crackles are heard initially in the lung bases and when severe in all [lung fields](/source/Lung_fields) indicate the development of [pulmonary edema](/source/Pulmonary_edema) (fluid in the [alveoli](/source/Pulmonary_alveolus)). [Cyanosis](/source/Cyanosis), indicates [deficiency of oxygen in the blood](/source/Hypoxemia), is a late sign of extremely severe pulmonary edema.[32] Other signs of left ventricular failure include a laterally displaced [apex beat](/source/Apex_beat) (which occurs when the heart is enlarged) and a [gallop rhythm](/source/Gallop_rhythm) (additional heart sounds), which may be heard as a sign of increased blood flow or increased intracardiac pressure. [Heart murmurs](/source/Heart_murmur) may indicate the presence of valvular heart disease, either as a cause (e.g., [aortic stenosis](/source/Aortic_stenosis)) or as a consequence (e.g., [mitral regurgitation](/source/Mitral_regurgitation)) of heart failure.[33] *Reverse* insufficiency of the left ventricle causes congestion in the blood vessels of the lungs so that symptoms are predominantly respiratory. Reverse insufficiency can be divided into the failure of the left atrium, the left ventricle, or both within the left circuit. Patients will experience [shortness of breath (dyspnea)](/source/Dyspnea) on exertion and, in severe cases, dyspnea at rest. Increasing breathlessness while lying down, called [orthopnea](/source/Orthopnea), also occurs. It can be measured by the number of pillows required to lie comfortably, with extreme cases of orthopnea forcing the patient to sleep sitting up. Another symptom of heart failure is [paroxysmal nocturnal dyspnea](/source/Paroxysmal_nocturnal_dyspnea): a sudden nocturnal attack of severe shortness of breath, usually occurring several hours after falling asleep.[34] There may be "[cardiac asthma](/source/Cardiac_asthma)" or [wheezing](/source/Wheezing). Impaired left ventricular *forward* function can lead to symptoms of poor systemic perfusion such as [dizziness](/source/Dizziness), [confusion](/source/Confusion), and cool extremities at rest. Loss of consciousness may also occur due to loss of blood supply to the brain.[35] ### Right-sided failure Severe peripheral pitting edema Right-sided heart failure is often caused by [pulmonary heart disease](/source/Pulmonary_heart_disease) (cor pulmonale), which is typically caused by issues with [pulmonary circulation](/source/Pulmonary_circulation) such as [pulmonary hypertension](/source/Pulmonary_hypertension) or [pulmonic stenosis](/source/Pulmonic_stenosis). Physical examination may reveal pitting peripheral edema, ascites, [liver enlargement](/source/Hepatomegaly), and [spleen enlargement](/source/Splenomegaly). [Jugular venous pressure](/source/Jugular_venous_pressure) is frequently assessed as a marker of fluid status, which can be accentuated by testing [hepatojugular reflux](/source/Abdominojugular_test). If the right ventricular pressure is increased, a [parasternal heave](/source/Parasternal_heave) which causes the compensatory increase in contraction strength may be present.[36] *Backward* failure of the right ventricle leads to congestion of systemic capillaries. This generates excess fluid accumulation in the body. This causes swelling under the skin ([peripheral edema](/source/Peripheral_edema) or [anasarca](/source/Anasarca)) and usually affects the dependent parts of the body first, causing foot and ankle swelling in people who are standing up and [sacral](/source/Sacrum) edema in people who are predominantly lying down. [Nocturia](/source/Nocturia) (frequent night-time urination) may occur when fluid from the legs is returned to the bloodstream while lying down at night. In progressively severe cases, ascites (fluid accumulation in the abdominal cavity causing swelling) and liver enlargement may develop. Significant liver congestion may result in impaired liver function ([congestive hepatopathy](/source/Congestive_hepatopathy)), jaundice, and [coagulopathy](/source/Coagulopathy) (problems of decreased or increased blood clotting).[37] ### Biventricular failure Dullness of the lung fields when [percussed](/source/Percussion_(medicine)) and reduced breath sounds at the base of the lungs may suggest the development of a [pleural effusion](/source/Pleural_effusion) (fluid collection [between the lung and the chest wall](/source/Pleural_cavity)). Though it can occur in isolated left- or right-sided heart failure, it is more common in biventricular failure because pleural veins drain into both the systemic and pulmonary venous systems. When unilateral, effusions are often right-sided.[38] If a person with a failure of one ventricle lives long enough, it will tend to progress to failure of both ventricles. For example, left ventricular failure allows pulmonary edema and pulmonary hypertension to occur, which increases stress on the right ventricle. Though still harmful, right ventricular failure is not as deleterious to the left side.[39] ## Causes Since heart failure is a [syndrome](/source/Syndrome) and not a disease, establishing the underlying cause is vital to diagnosis and treatment.[40][31] In heart failure, the structure or the function of the heart or in some cases both are altered.[6]: 3612 Heart failure is the potential end stage of all heart diseases.[41] Common causes of heart failure include [coronary artery disease](/source/Coronary_artery_disease) – including a previous [myocardial infarction](/source/Myocardial_infarction) (heart attack), [high blood pressure](/source/Hypertension), [atrial fibrillation](/source/Atrial_fibrillation), and [valvular heart disease](/source/Valvular_heart_disease) – [excessive alcohol use](/source/Alcohol_use_disorder), infection, and [cardiomyopathy](/source/Cardiomyopathy) of an unknown cause.[9][4]: e279[6]: Table 5 In addition, viral infection and subsequent [myocarditis](/source/Myocarditis) – inflammation of the heart's myocardial tissue – can similarly contribute to the development of heart failure. Genetic predisposition plays an important role. If more than one cause is present, progression is more likely and prognosis is worse.[42] [Heart damage](/source/Cardiomyopathy) can predispose a person to develop heart failure later in life and has many causes including systemic viral infections (e.g., [HIV](/source/HIV%2FAIDS)), [chemotherapeutic agents](/source/Chemotherapeutic_agent) such as [daunorubicin](/source/Daunorubicin), [cyclophosphamide](/source/Cyclophosphamide), [trastuzumab](/source/Trastuzumab) and [substance use disorders](/source/Substance_use_disorder) of substances such as [alcohol](/source/Alcoholic_beverage), [cocaine](/source/Cocaine), and [methamphetamine](/source/Methamphetamine). An uncommon cause is exposure to certain toxins such as [lead](/source/Lead) and [cobalt](/source/Cobalt). Additionally, [infiltrative disorders](/source/Infiltrative_disorders) such as [amyloidosis](/source/Amyloidosis) and [connective tissue diseases](/source/Connective_tissue_disease) such as [systemic lupus erythematosus](/source/Systemic_lupus_erythematosus) have similar consequences. [Obstructive sleep apnea](/source/Obstructive_sleep_apnea) (a condition of sleep wherein disordered breathing overlaps with obesity, hypertension, and/or diabetes) is regarded as an independent cause of heart failure.[43] Recent reports from [clinical trials](/source/Clinical_trial) have also linked variation in blood pressure to heart failure[44][45] and cardiac changes that may give rise to heart failure.[46] ### High-output heart failure [High-output heart failure](/source/High-output_heart_failure) happens when the amount of blood pumped out is more than typical and the heart cannot keep up.[47] This can occur in [overload](/source/Volume_overload) situations such as blood or serum infusions, kidney diseases, chronic severe [anemia](/source/Anemia), [beriberi](/source/Beriberi) (vitamin B1/[thiamine](/source/Thiamine) deficiency), [hyperthyroidism](/source/Hyperthyroidism), [cirrhosis](/source/Cirrhosis), [Paget's disease](/source/Paget's_disease_of_bone), [multiple myeloma](/source/Multiple_myeloma), [arteriovenous fistulae](/source/Arteriovenous_fistula), or [arteriovenous malformations](/source/Arteriovenous_malformation).[48][49] ### Acute decompensation Main article: [Acute decompensated heart failure](/source/Acute_decompensated_heart_failure) [Kerley B lines](/source/Kerley_B_lines) in [radiograph](/source/Radiograph) of acute cardiac decompensation. The short, horizontal lines can be found everywhere in the [right lung](/source/Right_lung). Chronic stable heart failure may easily [decompensate](/source/Decompensation) (fail to meet the body's metabolic needs). This most commonly results from a concurrent illness (such as [myocardial infarction](/source/Myocardial_infarction) (a heart attack) or [pneumonia](/source/Pneumonia)), [abnormal heart rhythms](/source/Cardiac_arrhythmia), uncontrolled [hypertension](/source/Hypertension), or a person's failure to maintain a fluid restriction, diet, or medication.[50] Other factors that may worsen CHF include: anemia, hyperthyroidism, excessive fluid or salt intake, and medication such as [NSAIDs](/source/Non-steroidal_anti-inflammatory_drug) and [thiazolidinediones](/source/Thiazolidinedione).[51] NSAIDs increase the risk twofold.[52] ### Medications A number of medications may cause or worsen the disease. This includes [NSAIDs](/source/Nonsteroidal_anti-inflammatory_drug), [COX-2 inhibitors](/source/COX-2_inhibitor), a number of [anesthetic](/source/Anesthetic) agents such as [ketamine](/source/Ketamine), thiazolidinediones, some [cancer medications](/source/Cancer#Medication), several [antiarrhythmic medications](/source/Antiarrhythmic_agent), [pregabalin](/source/Pregabalin), [alpha-2 adrenergic receptor agonists](/source/Alpha-2_adrenergic_receptor_agonist), [minoxidil](/source/Minoxidil), [itraconazole](/source/Itraconazole), [cilostazol](/source/Cilostazol), [anagrelide](/source/Anagrelide), [stimulants](/source/Stimulant) (e.g., [methylphenidate](/source/Methylphenidate)), [tricyclic antidepressants](/source/Tricyclic_antidepressant), [lithium](/source/Lithium_(medication)), [antipsychotics](/source/Antipsychotic), [dopamine agonists](/source/Dopamine_agonist), [TNF inhibitors](/source/TNF_inhibitor), [calcium channel blockers](/source/Calcium_channel_blocker) (especially [verapamil](/source/Verapamil) and [diltiazem](/source/Diltiazem)[53][54]), [salbutamol](/source/Salbutamol), and [tamsulosin](/source/Tamsulosin).[55] By inhibiting the formation of [prostaglandins](/source/Prostaglandin), NSAIDs may exacerbate heart failure through several mechanisms, including promotion of fluid retention, increasing [blood pressure](/source/Systemic_vascular_resistance), and decreasing a person's response to diuretic medications.[55] Similarly, the ACC/AHA recommends against using COX-2 inhibitor medications in people with heart failure.[55] Thiazolidinediones have been strongly linked to new cases of heart failure and worsening of pre-existing congestive heart failure due to their association with weight gain and fluid retention.[55] Certain calcium channel blockers, such as [diltiazem](/source/Diltiazem) and [verapamil](/source/Verapamil), are known to [decrease the force with which the heart ejects blood](/source/Inotrope#Negative_inotropic_agents); thus, these are not recommended in people with heart failure with a reduced ejection fraction.[55] Breast cancer patients are at high risk of heart failure due to several factors.[56] After analyzing data from 26 studies (836,301 patients), the recent meta-analysis found that breast cancer survivors demonstrated a higher risk of heart failure within the first ten years after diagnosis (hazard ratio = 1.21; 95% CI: 1.1, 1.33).[57] The pooled incidence of heart failure in breast cancer survivors was 4.44 (95% CI 3.33-5.92) per 1000 person-years of follow-up.[57] ### Supplements Certain [alternative medicines](/source/Alternative_medicine) carry a risk of exacerbating existing heart failure, and are not recommended.[55] This includes [aconite](/source/Aconitum), [ginseng](/source/Ginseng), [gossypol](/source/Gossypol), [gynura](/source/Gynura), [licorice](/source/Licorice), [lily of the valley](/source/Lily_of_the_valley), [tetrandrine](/source/Tetrandrine), and [yohimbine](/source/Yohimbine).[55] Aconite can cause abnormally slow heart rates and abnormal heart rhythms such as ventricular tachycardia.[55] Ginseng can cause abnormally low or high blood pressure and may interfere with the effects of diuretic medications. Gossypol can increase the effects of diuretics, leading to toxicity. Gynura can cause low blood pressure. Licorice can worsen heart failure by increasing blood pressure and promoting fluid retention.[55] Lily of the Valley can cause abnormally slow heart rates with mechanisms similar to those of digoxin. Tetrandrine can lower blood pressure by inhibiting [L-type calcium channels](/source/L-type_calcium_channel). Yohimbine can exacerbate heart failure by increasing blood pressure through alpha-2 adrenergic receptor antagonism.[55] ## Pathophysiology Main article: [Pathophysiology of heart failure](/source/Pathophysiology_of_heart_failure) Model of a normal heart (left); and a weakened heart, with over-stretched muscle and dilation of [left ventricle](/source/Left_ventricle) (right); both during [diastole](/source/Diastole) Heart failure is caused by any condition that reduces the efficiency of the heart muscle, through damage or [overloading](/source/Volume_overload). Over time, these increases in workload, which are mediated by long-term activation of neurohormonal systems such as the [renin–angiotensin system](/source/Renin%E2%80%93angiotensin_system) and the sympathoadrenal system, lead to [fibrosis](/source/Fibrosis), dilation, and structural changes in the shape of the left ventricle from elliptical to spherical.[23] The heart of a person with heart failure may have a reduced force of contraction due to overloading of the [ventricle](/source/Ventricle_(heart)). In a normal heart, increased filling of the ventricle results in increased contraction force by the [Frank–Starling law of the heart](/source/Frank%E2%80%93Starling_law_of_the_heart), and thus a rise in [cardiac output](/source/Cardiac_output). In heart failure, this mechanism fails, as the ventricle is loaded with blood to the point where heart muscle contraction becomes less efficient. This is due to the reduced ability to cross-link [actin](/source/Actin) and [myosin](/source/Myosin) [myofilaments](/source/Myofilament) in over-stretched heart muscle.[58] ## Diagnosis No diagnostic criteria have been agreed on as the [gold standard](/source/Gold_standard_(test)) for heart failure, especially [heart failure with preserved ejection fraction](/source/Heart_failure_with_preserved_ejection_fraction) (HFpEF). In the [UK](/source/UK), the [National Institute for Health and Care Excellence](/source/National_Institute_for_Health_and_Care_Excellence) recommends measuring [N-terminal pro-BNP (NT-proBNP)](/source/N-terminal_prohormone_of_brain_natriuretic_peptide) followed by an [ultrasound of the heart](/source/Echocardiography) if positive.[15] In [Europe](/source/Europe), the [European Society of Cardiology](/source/European_Society_of_Cardiology), and in the United States, the [AHA](/source/American_Heart_Association)/[ACC](/source/American_College_of_Cardiology)/[HFSA](/source/Heart_Failure_Society_of_America), recommend measuring NT-proBNP or BNP followed by an ultrasound of the heart if positive.[6][4] This is recommended in those with symptoms consistent with heart failure such as [shortness of breath](/source/Shortness_of_breath).[4] The [European Society of Cardiology](/source/European_Society_of_Cardiology) defines the diagnosis of heart failure as symptoms and signs consistent with heart failure in combination with "objective evidence of cardiac structural or functional abnormalities".[6] This definition is consistent with an international 2021 report termed "Universal Definition of Heart Failure".[6]: 3613 Score-based algorithms have been developed to help in the diagnosis of [HFpEF](/source/Heart_failure_with_preserved_ejection_fraction), which can be challenging for physicians to diagnose.[6]: 3630 The [AHA](/source/American_Heart_Association)/[ACC](/source/American_College_of_Cardiology)/[HFSA](/source/Heart_Failure_Society_of_America) defines heart failure as symptoms and signs consistent with heart failure in combination with shown "structural and functional alterations of the heart as the underlying cause for the clinical presentation", for HFmrEF and HFpEF specifically requiring "evidence of spontaneous or provokable increased left ventricle filling pressures".[4]: e276–e277 ### Algorithms The [European Society of Cardiology](/source/European_Society_of_Cardiology) has developed a diagnostic algorithm for [HFpEF](/source/Heart_failure_with_preserved_ejection_fraction), named HFA-PEFF.[6]: 3630[59] HFA-PEFF considers symptoms and signs, typical clinical demographics (obesity, hypertension, diabetes, elderly, atrial fibrillation), and diagnostic laboratory tests, ECG, and echocardiography.[4]: e277[59] ### Classification #### "Left", "right" and mixed heart failure One historical method of categorizing heart failure is by the side of the heart involved (left heart failure versus right heart failure). Right heart failure was thought to compromise blood flow to the lungs compared to left heart failure compromising blood flow to the [aorta](/source/Aorta) and consequently to the brain and the remainder of the body's systemic circulation. However, mixed presentations are common, and left heart failure is a common cause of right heart failure.[60] #### By ejection fraction A more accurate classification of heart failure type is made by measuring [ejection fraction](/source/Ejection_fraction), or the proportion of blood pumped out of the heart during a single contraction.[61] Ejection fraction is given as a percentage, with the normal range being between 50% and 75%.[61] The types are: 1. [Heart failure with reduced ejection fraction](/source/Heart_failure_with_reduced_ejection_fraction) (HFrEF): Synonyms no longer recommended are "heart failure due to left ventricular systolic dysfunction" and "systolic heart failure".[62] HFrEF is associated with an ejection fraction less than 40%.[63] 1. Heart failure with mildly reduced ejection fraction (HFmrEF), previously called "heart failure with mid-range ejection fraction",[64] is defined by an ejection fraction of 41–49%.[64] 1. [Heart failure with preserved ejection fraction](/source/Heart_failure_with_preserved_ejection_fraction) (HFpEF): Synonyms no longer recommended include "diastolic heart failure" and "heart failure with normal ejection fraction".[10][19] HFpEF occurs when the left ventricle contracts normally during systole, but the ventricle is stiff and does not relax normally during diastole, which impairs filling.[10] 1. Heart failure with recovered ejection fraction (HFrecovEF or HFrecEF): patients previously with HFrEF with complete normalization of left ventricular ejection (≥50%).[65][66] Heart failure may also be classified as acute or chronic. Chronic heart failure is a long-term condition, usually kept stable by the treatment of symptoms. [Acute decompensated heart failure](/source/Acute_decompensated_heart_failure) is a worsening of chronic heart failure symptoms, which can result in [acute respiratory distress](/source/Acute_respiratory_distress).[67] [High-output heart failure](/source/High-output_heart_failure) can occur when there is increased cardiac demand that results in increased left ventricular diastolic pressure which can develop into pulmonary congestion (pulmonary edema).[47] Several terms are closely related to heart failure and may be the cause of heart failure, but should not be confused with it. [Cardiac arrest](/source/Cardiac_arrest) and [asystole](/source/Asystole) refer to situations in which no cardiac output occurs at all. Without urgent treatment, these events result in sudden death. [Myocardial infarction](/source/Myocardial_infarction) (heart attack) refers to heart muscle damage due to insufficient blood supply, usually as a result of a blocked [coronary artery](/source/Coronary_artery). [Cardiomyopathy](/source/Cardiomyopathy) refers specifically to problems within the heart muscle, and these problems can result in heart failure.[68] Ischemic cardiomyopathy implies that the cause of muscle damage is coronary artery disease. [Dilated cardiomyopathy](/source/Dilated_cardiomyopathy) implies that the muscle damage has resulted in enlargement of the heart.[69] [Hypertrophic cardiomyopathy](/source/Hypertrophic_cardiomyopathy) involves enlargement and *thickening* of the heart muscle.[70] ### Ultrasound An [echocardiogram](/source/Echocardiogram) ([ultrasound](/source/Ultrasound) of the heart) is commonly used to support a clinical diagnosis of heart failure. This can determine the [stroke volume](/source/Stroke_volume) (SV, the amount of blood in the heart that exits the ventricles with each beat), the [end-diastolic volume](/source/End-diastolic_volume) (EDV, the total amount of blood at the end of diastole), and the SV in proportion to the EDV, a value known as the [ejection fraction](/source/Ejection_fraction) (EF). In pediatrics, the [shortening fraction](/source/Shortening_fraction) is the preferred measure of systolic function. Normally, the EF should be between 50 and 70%; in systolic heart failure, it drops below 40%. Echocardiography can also identify valvular heart disease and assess the state of the [pericardium](/source/Pericardium) (the connective tissue sac surrounding the heart). Echocardiography may also aid in deciding specific treatments, such as medication, insertion of an [implantable cardioverter-defibrillator](/source/Implantable_cardioverter-defibrillator), or [cardiac resynchronization therapy](/source/Cardiac_resynchronization_therapy). Echocardiography can also help determine if acute myocardial ischemia is the precipitating cause, and may manifest as regional wall motion abnormalities on echo.[71] A carotid ultrasound was found to assist with determining whether males aged over 60 were at risk of developing heart failure in the future. The ultrasound scans the [carotid arteries](/source/Carotid_arteries) which carry blood to the brain, with men that have less flexible arteries being at greater risk.[72][73] - Ultrasound showing severe systolic heart failure[74] - Ultrasound showing severe systolic heart failure[74] - Ultrasound of the lungs showing edema due to severe systolic heart failure[74] - Ultrasound showing severe systolic heart failure[74] - Ultrasound showing severe systolic heart failure[74] ### Chest X-ray [Chest radiograph](/source/Chest_radiograph) of a lung with distinct [Kerley B lines](/source/Kerley_lines), as well as an [enlarged heart](/source/Cardiomegaly) (as shown by an increased [cardiothoracic ratio](/source/Cardiothoracic_ratio), cephalization of pulmonary veins, and minor [pleural effusion](/source/Pleural_effusion) as seen for example in the right [horizontal fissure](/source/Horizontal_fissure_of_right_lung). Yet, no obvious lung edema is seen. Overall, this indicates intermediate severity (stage II) heart failure. [Chest X-rays](/source/Chest_X-ray) are frequently used to aid in the diagnosis of CHF. In a person who is compensated, this may show [cardiomegaly](/source/Cardiomegaly) (visible enlargement of the heart), quantified as the [cardiothoracic ratio](/source/Cardiothoracic_ratio) (proportion of the heart size to the chest). In left ventricular failure, evidence may exist of vascular redistribution (upper lobe blood diversion or cephalization), [Kerley lines](/source/Kerley_lines), [cuffing of the areas around](/source/Peribronchial_cuffing) the [bronchi](/source/Bronchi), and interstitial edema. Ultrasound of the lung may also detect Kerley lines.[75] - Congestive heart failure with small bilateral effusions - Kerley B lines ### Electrophysiology An [electrocardiogram](/source/Electrocardiogram) (ECG or EKG) may be used to identify [arrhythmias](/source/Arrhythmia), [ischemic heart disease](/source/Ischemic_heart_disease), [right](/source/Right_ventricular_hypertrophy) and [left ventricular hypertrophy](/source/Left_ventricular_hypertrophy), and presence of conduction delay or abnormalities (e.g. [left bundle branch block](/source/Left_bundle_branch_block)). Although these findings are not specific to the diagnosis of heart failure, a normal ECG virtually excludes left ventricular systolic dysfunction.[76] ### Blood tests [N-terminal pro-BNP (NT-proBNP)](/source/N-terminal_prohormone_of_brain_natriuretic_peptide) is the favored biomarker for the diagnosis of heart failure, according to guidelines published 2018 by [NICE](/source/National_Institute_for_Health_and_Care_Excellence) in the [UK](/source/United_Kingdom).[3] [Brain natriuretic peptide 32](/source/Brain_natriuretic_peptide_32) (BNP) is another biomarker commonly tested for heart failure.[77][6][78] An elevated NT-proBNP or BNP is a specific test indicative of heart failure. Additionally, NT-proBNP or BNP can be used to differentiate between causes of dyspnea due to heart failure from other causes of dyspnea. If a myocardial infarction is suspected, various [cardiac markers](/source/Cardiac_marker) may be used. [Blood tests](/source/Blood_test) routinely performed include [electrolytes](/source/Electrolyte) ([sodium](/source/Sodium), [potassium](/source/Potassium)), measures of [kidney function](/source/Kidney_function), [liver function tests](/source/Liver_function_tests), [thyroid function tests](/source/Thyroid_function_test), a [complete blood count](/source/Complete_blood_count), and often [C-reactive protein](/source/C-reactive_protein) if infection is suspected. [Hyponatremia](/source/Hyponatremia) (low serum sodium concentration) is common in heart failure. [Vasopressin](/source/Vasopressin) levels are usually increased, along with renin, angiotensin II, and catecholamines to compensate for reduced circulating volume due to inadequate cardiac output. This leads to increased fluid and sodium retention in the body; the rate of fluid retention is higher than the rate of sodium retention in the body, this phenomenon causes hypervolemic hyponatremia (low sodium concentration due to high body fluid retention). This phenomenon is more common in older women with low body mass. Severe hyponatremia can result in accumulation of fluid in the brain, causing [cerebral edema](/source/Cerebral_edema) and [intracranial hemorrhage](/source/Intracranial_hemorrhage).[79] ### Angiography [Angiography](/source/Angiography) is the [X-ray](/source/X-ray) imaging of [blood vessels](/source/Blood_vessel), which is done by injecting contrast agents into the [bloodstream](/source/Circulatory_system) through a thin plastic tube ([catheter](/source/Catheter)), which is placed directly in the blood vessel. X-ray images are called angiograms.[80] Heart failure may be the result of coronary artery disease, and its prognosis depends in part on the ability of the [coronary arteries](/source/Coronary_artery) to supply blood to the [myocardium](/source/Myocardium) (heart muscle). As a result, [coronary catheterization](/source/Coronary_catheterization) may be used to identify possibilities for revascularisation through [percutaneous coronary intervention](/source/Percutaneous_coronary_intervention) or [bypass surgery](/source/Coronary_artery_bypass_surgery). ### Staging Heart failure is commonly stratified by the degree of functional impairment conferred by the severity of the heart failure, as reflected in the [New York Heart Association (NYHA) functional classification](/source/New_York_Heart_Association_Functional_Classification).[81] The NYHA functional classes (I–IV) begin with class I, which is defined as a person who experiences no limitation in any activities and has no symptoms from ordinary activities. People with NYHA class II heart failure have slight, mild limitations with everyday activities; the person is comfortable at rest or with mild exertion. With NYHA class III heart failure, a marked limitation occurs with any activity; the person is comfortable only at rest. A person with NYHA class IV heart failure is symptomatic at rest and becomes quite uncomfortable with any physical activity. This score documents the severity of symptoms and can be used to assess response to treatment. While its use is widespread, the NYHA score is not very reproducible and does not reliably predict walking distance or exercise tolerance on formal testing.[82] In its 2001 guidelines, the [American College of Cardiology](/source/American_College_of_Cardiology)/[American Heart Association](/source/American_Heart_Association) working group introduced four stages of heart failure:[83] - Stage A: People at high risk for developing HF in the future, but no functional or structural heart disorder - Stage B: A structural heart disorder, but no symptoms at any stage - Stage C: Previous or current symptoms of heart failure in the context of an underlying structural heart problem, but managed with medical treatment - Stage D: Advanced disease requiring hospital-based support, a heart transplant, or [palliative care](/source/Palliative_care) The ACC staging system is useful since stage A encompasses "pre-heart failure" – a stage where intervention with treatment can presumably prevent progression to overt symptoms. ACC stage A does not have a corresponding NYHA class. ACC stage B would correspond to NYHA class I. ACC stage C corresponds to NYHA class II and III, while ACC stage D overlaps with NYHA class IV. - The degree of coexisting illness: i.e. heart failure/systemic hypertension, heart failure/pulmonary hypertension, heart failure/diabetes, heart failure/kidney failure, etc. - Whether the problem is primarily increased venous back pressure ([preload](/source/Preload_(cardiology))), or failure to supply adequate arterial perfusion ([afterload](/source/Afterload)) - Whether the abnormality is due to low cardiac output with high [systemic vascular resistance](/source/Systemic_vascular_resistance) or high cardiac output with low vascular resistance (low-output heart failure vs. high-output heart failure) ### Histopathology Siderophages (one indicated by white arrow) and pulmonary congestion, indicating left [congestive heart failure](/source/Congestive_heart_failure) [Histopathology](/source/Histopathology) can diagnose heart failure in [autopsies](/source/Autopsy). The presence of [siderophages](/source/Siderophage) indicates chronic left-sided heart failure, but is not [specific](/source/Sensitivity_and_specificity) for it.[84] It is also indicated by congestion of the pulmonary circulation. ## Prevention A person's risk of developing heart failure is inversely related to the level of [physical activity](/source/Physical_exercise). Those who achieved at least 500 [MET-minutes/week](/source/Metabolic_equivalent) (the recommended minimum by U.S. guidelines) had lower heart failure risk than individuals who did not report exercising during their free time; the reduction in heart failure risk was even greater in those who engaged in higher levels of physical activity than the recommended minimum.[85] Heart failure can also be prevented by lowering high blood pressure and high blood cholesterol, and by controlling diabetes. Maintaining a healthy weight, and decreasing sodium, alcohol, and sugar intake, may help. Additionally, avoiding tobacco use has been shown to lower the risk of heart failure.[86] According to [Johns Hopkins](/source/Johns_Hopkins_University) and the [American Heart Association](/source/American_Heart_Association) there are a few ways to help prevent a cardiac event. Johns Hopkins states that stopping tobacco use, reducing high blood pressure, physical activity, and nutrition can drastically affect the chances of developing heart disease. High blood pressure accounts for most cardiovascular deaths. High blood pressure can be lowered into the normal range by making dietary decisions such as consuming less salt. Exercise also helps to bring blood pressure back down. One of the best ways to help avoid heart failure is to promote healthier eating habits like eating more vegetables, fruits, grains, and lean protein.[87] Diabetes is a major risk factor for heart failure. For women with Coronary Heart disease (CHD), diabetes was the strongest risk factor for heart failure.[88] Diabetic women with depressed creatinine clearance or elevated BMI were at the highest risk of heart failure. While the annual incidence rate of heart failure for non-diabetic women with no risk factors is 0.4%, the annual incidence rate for diabetic women with elevated body mass index (BMI) and depressed creatinine clearance was 7% and 13%, respectively.[89] ## Management Main article: [Management of heart failure](/source/Management_of_heart_failure) Treatment focuses on improving the symptoms and preventing the progression of the disease. Reversible causes of heart failure also need to be addressed (e.g. [infection](/source/Infection), alcohol ingestion, anemia, [thyrotoxicosis](/source/Thyrotoxicosis), [arrhythmia](/source/Heart_arrhythmia), and hypertension). Treatments include lifestyle and pharmacological modalities, and occasionally various forms of device therapy. Rarely, cardiac transplantation is used as an effective treatment when heart failure has reached the end stage.[90] ### Acute decompensation Main article: [Acute decompensated heart failure](/source/Acute_decompensated_heart_failure) In [acute decompensated heart failure](/source/Acute_decompensated_heart_failure), the immediate goal is to re-establish adequate perfusion and oxygen delivery to end organs. This entails ensuring that [airway, breathing, and circulation](/source/ABC_(medicine)) are adequate. Immediate treatments usually involve some combination of vasodilators such as [nitroglycerin](/source/Nitroglycerin_(medication)), diuretics such as [furosemide](/source/Furosemide), and possibly [noninvasive positive pressure ventilation](/source/Noninvasive_positive_pressure_ventilation). [Supplemental oxygen](/source/Oxygen_therapy) is indicated in those with oxygen saturation levels below 90%, but is not recommended in those with normal oxygen levels in the normal atmosphere.[91] ### Chronic management The goals of treatment for people with chronic heart failure are prolonging life, preventing acute decompensation, and reducing symptoms, allowing for greater activity. Heart failure can result from a variety of conditions. In considering therapeutic options, excluding reversible causes is of primary importance, including [thyroid disease](/source/Thyroid_disease), [anemia](/source/Anemia), chronic [tachycardia](/source/Tachycardia), [alcohol use disorder](/source/Alcohol_use_disorder), [hypertension](/source/Hypertension), and dysfunction of one or more [heart valves](/source/Heart_valves). Treatment of the underlying cause is usually the first approach to treating heart failure. In most cases, though, either no primary cause is found or treatment of the primary cause does not restore normal heart function. In these cases, [behavioral](/source/Behavioral_treatments), [medical](/source/Medical_treatment) and [device](/source/Medical_device) treatment strategies exist that can provide a significant improvement in outcomes, including the relief of symptoms, exercise tolerance, and a decrease in the likelihood of [hospitalization](/source/Hospitalization) or death. Breathlessness rehabilitation for [chronic obstructive pulmonary disease](/source/Chronic_obstructive_pulmonary_disease) and heart failure has been proposed with exercise training as a core component. Rehabilitation should also include other interventions to address shortness of breath including the psychological and educational needs of people and the needs of caregivers.[92] [Iron supplementation](/source/Iron_supplementation) appears to reduce hospitalization but not all-cause mortality in patients with iron deficiency and heart failure.[93] #### Advance care planning The latest evidence indicates that advance care planning (ACP) may help to increase documentation by medical staff regarding discussions with participants and improve an individual's depression.[94] This involves discussing an individual's future care plan, preferences, and values. The findings are, however, based on low-quality evidence.[94] #### Monitoring The various measures often used to assess the progress of people being treated for heart failure include [fluid balance](/source/Fluid_balance) (calculation of fluid intake and excretion) and monitoring [body weight](/source/Body_weight) (which in the shorter term reflects fluid shifts).[95] Remote monitoring can be effective to reduce complications for people with heart failure.[96][97] #### Lifestyle Behavior modification is a primary consideration in chronic heart failure management programs, with [dietary guidelines](/source/Dietary_guidelines) regarding [fluid](/source/Drinking_water) and [salt](/source/Sodium_chloride) intake.[98] Fluid restriction is important to reduce fluid retention in the body and to correct the hyponatremic status of the body.[79] The evidence of the benefit of reducing salt, however, is poor as of 2018.[99] Thirst is a common and burdensome symptom for patients to cope with. Chewing gum is an effective intervention to relieve thirst in patients experiencing heart failure, although patient acceptability remains an issue.[100] #### Exercise and physical activity Exercise should be encouraged and tailored to suit an individual's capabilities. A meta-analysis found that center-based group interventions delivered by a physiotherapist help promote physical activity in HF.[101] There is a need for additional training for physiotherapists in delivering behavior change intervention alongside an exercise program. An intervention is expected to be more efficacious in encouraging physical activity than the usual care if it includes *Prompts and cues* to walk or exercise, like a phone call or a text message. It is helpful if a trusted clinician provides explicit advice to engage in physical activity (*Credible source*). Another highly effective strategy is to place objects that will serve as a cue to engage in physical activity in the person's everyday environment (*Adding object to the environment*; e.g., exercise step or treadmill). Encouragement to walk or exercise in various settings beyond CR (e.g., home, neighborhood, parks) is also promising (*Generalisation of target behavior*). Additional promising strategies are *Graded tasks* (e.g., gradual increase in intensity and duration of exercise training), *Self-monitoring*, *Monitoring of physical activity by others without feedback*, *Action planning*, and *Goal-setting*.[102] The inclusion of regular physical conditioning as part of a [cardiac rehabilitation](/source/Cardiac_rehabilitation) program can significantly improve [quality of life](/source/Quality_of_life) and reduce the risk of hospital admission for worsening symptoms, but no evidence shows a reduction in mortality rates as a result of exercise. Home visits and regular monitoring at heart-failure clinics reduce the need for hospitalization and improve [life expectancy](/source/Life_expectancy).[103] #### Medication Quadruple medical therapy using a combination of [angiotensin receptor-neprilysin inhibitors (ARNI)](/source/Sacubitril%2Fvalsartan), [beta blockers](/source/Beta_blocker), [mineralocorticoid receptor antagonists (MRA)](/source/Antimineralocorticoid), and [sodium/glucose cotransporter 2 inhibitors (SGLT2 inhibitors)](/source/SGLT2_inhibitor) is the standard of care as of 2021 for heart failure with reduced ejection fraction (HFrEF).[104][105] There is no convincing evidence for pharmacological treatment of heart failure with preserved ejection fraction (HFpEF).[6] Medication for HFpEF is symptomatic treatment with diuretics to treat congestion.[6] Managing risk factors and comorbidities such as [hypertension](/source/Hypertension) is recommended in HFpEF.[6] Inhibitors of the [renin–angiotensin system](/source/Renin%E2%80%93angiotensin_system) (RAS) are recommended for heart failure. The [angiotensin receptor-neprilysin inhibitors (ARNI) sacubitril/valsartan](/source/Sacubitril%2Fvalsartan) is recommended as the first choice of RAS inhibitors in American guidelines published by AHA/ACC in 2022.[4] Use of [ACE inhibitor](/source/ACE_inhibitor), or [angiotensin receptor blockers](/source/Angiotensin_receptor_blockers) (ARBs) if the person develops a long-term cough as a side effect of the ACE-I,[106] is associated with improved survival, fewer hospitalizations for heart failure exacerbations, and improved quality of life in people with heart failure.[107] European guidelines published by ESC in 2021 recommends that ARNI should be used in those who still have symptoms while on an ACE-I or [ARB](/source/Angiotensin_receptor_blocker), [beta blocker](/source/Beta_blocker), and a [mineralocorticoid receptor antagonist](/source/Mineralocorticoid_receptor_antagonist). Use of the combination agent ARNI requires the cessation of ACE-I or ARB therapy at least 36 hours before its initiation.[4] [Beta-adrenergic blocking agents (beta blockers)](/source/Beta_blockers) add to the improvement in symptoms and [mortality](/source/Case_fatality_rate) provided by ACE-I/ARB.[107][108] The mortality benefits of beta blockers in people with systolic dysfunction who also have [atrial fibrillation](/source/Atrial_fibrillation) is more limited than in those who do not have it.[109] If the ejection fraction is not diminished (HFpEF), the benefits of beta blockers are more modest; a decrease in mortality has been observed, but reduction in hospital admission for uncontrolled symptoms has not been observed.[110] In people who are intolerant of ACE-I and ARB or who have significant kidney dysfunction, the use of combined [hydralazine](/source/Hydralazine) and a long-acting nitrate, such as [isosorbide dinitrate](/source/Isosorbide_dinitrate), is an effective alternate strategy. This regimen has been shown to reduce mortality in people with moderate heart failure.[111] It is especially beneficial in the black population.[a][111] Use of a [mineralocorticoid antagonist](/source/Mineralocorticoid_antagonist), such as [spironolactone](/source/Spironolactone) or [eplerenone](/source/Eplerenone), in addition to beta blockers and ACE-I, can improve symptoms and reduce mortality in people with symptomatic heart failure with reduced ejection fraction (HFrEF).[17] [SGLT2 inhibitors](/source/SGLT2_inhibitor) are used for heart failure with reduced ejection fraction as they have demonstrated benefits in reducing hospitalizations and mortality, regardless of whether an individual has comorbid Type 2 Diabetes or not.[4][112] #### Other medications Second-line medications for CHF do not confer a mortality benefit. [Digoxin](/source/Digoxin) is one such medication. Its narrow therapeutic window, a high degree of toxicity, and the failure of multiple trials to show a mortality benefit have reduced its role in clinical practice. It is now used in only a small number of people with refractory symptoms, who are in atrial fibrillation, and/or who have chronic hypotension.[113][114] Diuretics have been a mainstay of treatment against symptoms of fluid accumulation, and include diuretics classes such as [loop diuretics](/source/Loop_diuretic) (such as [furosemide](/source/Furosemide)), [thiazide-like diuretics](/source/Thiazide-like_diuretic), and [potassium-sparing diuretics](/source/Potassium-sparing_diuretic). Although widely used, evidence on their efficacy and safety is limited, except for [mineralocorticoid antagonists](/source/Mineralocorticoid_antagonist) such as [spironolactone](/source/Spironolactone).[17][115] Anemia is an independent factor in mortality in people with chronic heart failure. Treatment of anemia significantly improves the quality of life for those with heart failure, often with a reduction in severity of the NYHA classification, and also improves mortality rates.[116][117] The [European Society of Cardiology](/source/European_Society_of_Cardiology) recommends screening for iron deficiency and treating with [intravenous iron](/source/Parenteral_iron) if deficiency is found.[6]: 3668–3669 The decision to anticoagulate people with HF, typically with left ventricular ejection fractions <35% is debated, but generally, people with coexisting atrial fibrillation, a prior embolic event, or conditions that increase the risk of an embolic event such as amyloidosis, left ventricular noncompaction, familial dilated cardiomyopathy, or a thromboembolic event in a first-degree relative.[83] [Vasopressin receptor antagonists](/source/Vasopressin_receptor_antagonist) can also treat heart failure. [Conivaptan](/source/Conivaptan) is the first medication approved by the US [Food and Drug Administration](/source/Food_and_Drug_Administration) for the treatment of euvolemic hyponatremia in those with heart failure.[79] In rare cases hypertonic 3% saline together with diuretics may be used to correct hyponatremia.[79] [Ivabradine](/source/Ivabradine) is recommended for people with symptomatic heart failure with reduced left ventricular ejection fraction who are receiving optimized guideline-directed therapy (as above) including the maximum tolerated dose of beta-blocker, have a normal heart rhythm and continue to have a resting heart rate above 70 beats per minute.[118] Ivabradine has been found to reduce the risk of hospitalization for heart failure exacerbations in this subgroup of people with heart failure.[118] #### Implanted devices In people with severe cardiomyopathy (left ventricular ejection fraction below 35%), or in those with recurrent VT or malignant arrhythmias, treatment with an automatic implantable cardioverter-defibrillator (AICD) is indicated to reduce the risk of severe life-threatening arrhythmias. The AICD does not improve symptoms or reduce the incidence of malignant arrhythmias but does reduce mortality from those arrhythmias, often in conjunction with antiarrhythmic medications. In people with left ventricular ejection (LVEF) below 35%, the incidence of [ventricular tachycardia](/source/Ventricular_tachycardia) or [sudden cardiac death](/source/Sudden_cardiac_death) is high enough to warrant AICD placement. Its use is therefore recommended in [AHA](/source/American_Hospital_Association)/[ACC](/source/American_College_of_Cardiology) guidelines.[21] [Cardiac contractility modulation](/source/Cardiac_contractility_modulation) (CCM) is a [treatment](/source/Therapy) for people with moderate to severe [left ventricular](/source/Heart#Chambers) systolic heart failure (NYHA classes II–IV), which enhances both the strength of ventricular [contraction](/source/Muscle_contraction) and the heart's pumping capacity. The CCM mechanism is based on stimulation of the cardiac muscle by [nonexcitatory electrical signals](/source/Action_potential#Refractory_period), which are delivered by a [pacemaker](/source/Artificial_cardiac_pacemaker)-like device. CCM is particularly suitable for the treatment of heart failure with normal [QRS complex](/source/QRS_complex) duration (120 ms or less) and has been demonstrated to improve the symptoms, quality of life, and exercise tolerance.[22][119][120][121][122] CCM is approved for use in Europe, and was approved by the Food and Drug Administration for use in the United States in 2019.[123][124][125] About one-third of people with an [LVEF](/source/LVEF) below 35% have markedly altered conduction to the ventricles, resulting in dyssynchronous depolarization of the right and left ventricles. This is especially problematic in people with left bundle branch block (blockage of one of the two primary conducting fiber bundles that originate at the base of the heart and carry depolarizing impulses to the left ventricle). Using a special pacing algorithm, biventricular [cardiac resynchronization therapy](/source/Cardiac_resynchronization_therapy) (CRT) can initiate a normal sequence of ventricular depolarization. In people with LVEF below 35% and prolonged QRS duration on ECG (LBBB or QRS of 150 ms or more), an improvement in symptoms and mortality occurs when CRT is added to standard medical therapy.[126] However, in the two-thirds of people without prolonged QRS duration, CRT may be harmful.[21][22][127] #### Surgical therapies People with the most severe heart failure may be candidates for [ventricular assist devices](/source/Ventricular_assist_device), which have commonly been used as a bridge to heart transplantation but have been used more recently as a destination treatment for advanced heart failure.[128] Coronary bypass surgery may also be used to move blood around clogged arteries in cases when heart failure is caused by arterial blockages.[129][130] In select cases, heart transplantation can be considered. While this may resolve the problems associated with heart failure, the person must generally remain on an immunosuppressive regimen to prevent rejection, which has its own significant downsides.[131] A major limitation of this treatment option is the scarcity of hearts available for transplantation. ### Palliative care People with heart failure often have significant symptoms, such as chest pain and shortness of breath. [Palliative care](/source/Palliative_care) should be initiated early in the HF trajectory, and should not be an option of last resort.[132] Palliative care can not only provide symptom management, but also assist with advanced care planning, goals of care in the case of a significant decline, and making sure the person has a medical [power of attorney](/source/Power_of_attorney) and discussed his or her wishes with this individual.[133] A 2016 and 2017 review found that palliative care is associated with improved outcomes, such as quality of life, symptom burden, and satisfaction with care.[132][134] Without transplantation, heart failure may not be reversible and heart function typically deteriorates with time. The growing number of people with stage IV heart failure (intractable symptoms of fatigue, shortness of breath, or chest pain at rest despite optimal medical therapy) should be considered for palliative care or [hospice](/source/Hospice), according to American College of Cardiology/American Heart Association guidelines.[133] ## Prognosis Prognosis in heart failure can be assessed in multiple ways, including clinical prediction rules and cardiopulmonary exercise testing. Clinical prediction rules use a composite of clinical factors such as laboratory tests and blood pressure to estimate prognosis. Among several [clinical prediction rules](/source/Clinical_prediction_rule) for prognosticating acute heart failure, the 'EFFECT rule' slightly outperformed other rules in stratifying people and identifying those at low risk of death during hospitalization or within 30 days.[135] Easy methods for identifying people that are low-risk are: - ADHERE Tree rule indicates that people with [blood urea nitrogen](/source/Blood_urea_nitrogen) < 43 mg/dL and [systolic blood pressure](/source/Systolic_blood_pressure) at least 115 mm Hg have less than 10% chance of inpatient death or complications. - BWH rule indicates that people with systolic blood pressure over 90 mm Hg, respiratory rate of 30 or fewer breaths per minute, serum sodium over 135 mmol/L, and no new ST–T wave changes have less than 10% chance of inpatient death or complications. A crucial method for assessing prognosis in people with advanced heart failure is cardiopulmonary exercise testing (CPX testing). CPX testing is usually required before heart transplantation as an indicator of prognosis. CPX testing involves the measurement of exhaled oxygen and carbon dioxide during exercise. The peak oxygen consumption ([VO2 max](/source/VO2_max)) is used as an indicator of prognosis. As a general rule, a VO2 max less than 12–14 cc/kg/min indicates poor survival and suggests that the person may be a candidate for a heart transplant. People with a VO2 max <10 cc/kg/min have a poorer prognosis. The most recent International Society for Heart and Lung Transplantation guidelines[136] also suggest two other parameters that can be used for evaluation of prognosis in advanced heart failure, the heart failure survival score and the use of a criterion of VE/VCO2 slope > 35 from the CPX test. The heart failure survival score is calculated using a combination of clinical predictors and the VO2 max from the CPX test. Heart failure is associated with significantly reduced physical and mental health, resulting in a markedly decreased quality of life.[137][138] With the exception of heart failure caused by reversible conditions, the condition usually worsens with time. Although some people survive many years, progressive disease is associated with an overall annual mortality rate of 10%.[139] Around 18 of every 1000 persons will experience an [ischemic stroke](/source/Ischemic_stroke) during the first year after diagnosis of HF. As the duration of follow-up increases, the stroke rate rises to nearly 50 strokes per 1000 cases of HF by 5 years.[140] ## Epidemiology In 2022, heart failure affected about 64 million people globally.[141] Overall, around 2% of adults have heart failure.[23] In those over the age of 75, rates are greater than 10%.[23] Rates are predicted to increase.[23] Increasing rates are mostly because of increasing lifespan, but also because of increased risk factors (hypertension, diabetes, dyslipidemia, and obesity) and improved survival rates from other types of cardiovascular disease (myocardial infarction, valvular disease, and arrhythmias).[142][143][144] Heart failure is the leading cause of hospitalization in people older than 65.[145] ### United States In the United States, heart failure affects 5.8 million people, and each year 550,000 new cases are diagnosed.[146] In 2011, heart failure was the most common reason for hospitalization for adults aged 85 years and older, and the second-most common for adults aged 65–84 years.[147] An estimated one in five adults at age 40 will develop heart failure during their remaining lifetimes and about half of people who develop heart failure die within 5 years of diagnosis.[148] Heart failure – much higher in African Americans, Hispanics, Native Americans, and recent immigrants from Eastern Europe countries – has been linked in these ethnic minority populations to the high incidence of diabetes and hypertension.[149] Nearly one of every four people (24.7%) hospitalized in the U.S. with congestive heart failure is readmitted within 30 days.[150] Additionally, more than 50% of people seek readmission within 6 months after treatment and the average duration of hospital stay is 6 days. Heart failure is a leading cause of hospital readmissions in the U.S. People aged 65 and older were readmitted at a rate of 24.5 per 100 admissions in 2011. In the same year, heart failure patients under Medicaid were readmitted at a rate of 30.4 per 100 admissions, and uninsured people were readmitted at a rate of 16.8 per 100 admissions. These are the highest readmission rates for both categories. Notably, heart failure was not among the top-10 conditions with the most 30-day readmissions among the privately insured.[151] ### United Kingdom In the UK, despite moderate improvements in prevention, heart failure rates have increased due to population growth and aging.[152] Overall heart failure rates are similar to the four most common causes of cancer (breast, lung, prostate, and colon) combined.[152] People from deprived backgrounds are more likely to be diagnosed with heart failure at a younger age.[152] ### Developing world In tropical countries, the most common cause of heart failure is valvular heart disease or some type of cardiomyopathy. As underdeveloped countries have become more affluent, the incidences of [diabetes](/source/Diabetes), [hypertension](/source/Hypertension), and [obesity](/source/Obesity) have increased, which have in turn raised the incidence of heart failure.[153] ### Sex Men have a higher incidence of heart failure, but the overall prevalence rate is similar in both sexes since women survive longer after the onset of heart failure.[154] Women tend to be older when diagnosed with heart failure (after [menopause](/source/Menopause)), they are more likely than men to have diastolic dysfunction, and seem to experience a lower overall quality of life than men after diagnosis.[154] ### Ethnicity Some sources state that people of [Asian](/source/Asian_people) descent are at a higher risk of heart failure than other ethnic groups.[155] Other sources, however, have found that rates of heart failure are similar to rates found in other ethnic groups.[156] ## History For centuries, the disease entity which would include many cases of what today would be called heart failure was *dropsy*; the term denotes generalized edema, a major manifestation of a failing heart, though also caused by other diseases. Writings of ancient civilizations include evidence of their acquaintance with dropsy and heart failure: Egyptians were the first to use [bloodletting](/source/Bloodletting) to relieve fluid accumulation and shortage of breath, and provided what may have been the first documented observations on heart failure in the [Ebers papyrus](/source/Ebers_papyrus) (around 1500 BCE).[157] Greeks described cases of dyspnea, fluid retention and fatigue compatible with heart failure.[158] Romans used the flowering plant *[Drimia maritima](/source/Drimia_maritima)* (sea squill), which contains [cardiac glycosides](/source/Cardiac_glycoside), for the treatment of dropsy;[159] descriptions pertaining to heart failure are also known in the civilizations of ancient India and China.[160] However, the manifestations of failing heart were understood in the context of these peoples' medical theories – including ancient Egyptian religion, [Hippocratic](/source/Hippocrates) [theory of humours](/source/Theory_of_Humours), or ancient [Indian](/source/Ayurveda#History) and [Chinese medicine](/source/Traditional_Chinese_medicine), and the current concept of heart failure had not developed yet.[158][160] Although shortage of breath had been connected to heart disease by [Avicenna](/source/Avicenna) round 1000 CE,[161] decisive for modern understanding of the nature of the condition were the description of [pulmonary circulation](/source/Pulmonary_circulation) by [Ibn al-Nafis](/source/Ibn_al-Nafis) in the 13th century, and of [systemic circulation](/source/Circulatory_system) by [William Harvey](/source/William_Harvey) in 1628.[158] The role of the heart in fluid retention began to be better appreciated, as *dropsy of the chest* (fluid accumulation in and around the lungs causing shortness of breath) became more familiar and the current concept of heart failure, which brings together swelling and shortage of breath due to fluid retention, began to be accepted, in the 17th and especially in the 18th century: [Richard Lower](/source/Richard_Lower_(physician)) linked dyspnea and foot swelling in 1679, and [Giovanni Maria Lancisi](/source/Giovanni_Maria_Lancisi) connected jugular vein distention with right ventricular failure in 1728.[161] Dropsy attributable to other causes, e.g. kidney failure, was differentiated in the 19th century.[162][163][164] The stethoscope, invented by [René Laennec](/source/Ren%C3%A9_Laennec) in 1819, [x-rays](/source/X-ray), discovered by [Wilhelm Röntgen](/source/Wilhelm_R%C3%B6ntgen) in 1895, and [electrocardiography](/source/Electrocardiography), described by [Willem Einthoven](/source/Willem_Einthoven) in 1903, facilitated the investigation of heart failure.[41][164] The 19th century also saw experimental and conceptual advances in the physiology of heart contraction, which led to the formulation of the [Frank-Starling law](/source/Frank-Starling_law) of the heart (named after physiologists [Otto Frank](/source/Otto_Frank_(physiologist)) and [Ernest Starling](/source/Ernest_Starling)), a remarkable advance in understanding mechanisms of heart failure.[165] One of the earliest treatments of heart failure, relief of swelling by bloodletting with various methods, including [leeches](/source/Hirudo_medicinalis#Medical_use), continued through the centuries.[166] Along with bloodletting, [Jean-Baptiste de Sénac](/source/Jean-Baptiste_de_S%C3%A9nac) in 1749 recommended [opiates](/source/Opiate) for acute shortage of breath due to heart failure.[164] In 1785, [William Withering](/source/William_Withering) described the therapeutic uses of the [foxglove](/source/Foxglove) genus of plants in the treatment of edema; their extract contains [cardiac glycosides](/source/Cardiac_glycoside), including digoxin, still used today in the treatment of heart failure.[159] The [diuretic effects of inorganic mercury salts](/source/Mercurial_diuretic), which were used to treat [syphilis](/source/Syphilis), had already been noted in the 16th century by [Paracelsus](/source/Paracelsus);[167] in the 19th century they were used by noted physicians like [John Blackall](/source/John_Blackall) and [William Stokes](/source/William_Stokes_(physician)).[168] In the meantime, [cannulae](/source/Cannula) (tubes) invented by English physician [Reginald Southey](/source/Reginald_Southey) in 1877 was another method of removing excess fluid by directly inserting into swollen limbs.[166] Use of organic mercury compounds as diuretics, beyond their role in syphilis treatment, started in 1920, though it was limited by their [parenteral](/source/Route_of_administration#Parenteral) route of administration and their side-effects.[168][169] Oral mercurial diuretics were introduced in the 1950s; so were thiazide diuretics, which caused less toxicity, and are still used.[41][168] Around the same time, the invention of echocardiography by [Inge Edler](/source/Inge_Edler) and [Hellmuth Hertz](/source/Carl_Hellmuth_Hertz) in 1954 marked a new era in the evaluation of heart failure.[41] In the 1960s, [loop diuretics](/source/Loop_diuretics) were added to available treatments of fluid retention, while a patient with heart failure received the first [heart transplant](/source/Heart_transplant) by [Christiaan Barnard](/source/Christiaan_Barnard).[41][168] Over the following decades, new drug classes found their place in heart failure therapeutics, including [vasodilators](/source/Vasodilation) like [hydralazine](/source/Hydralazine); [renin-angiotensin system](/source/Renin-angiotensin_system) inhibitors; and [beta-blockers](/source/Beta-blockers).[170][171] ## Economics In 2011, nonhypertensive heart failure was one of the 10 most expensive conditions seen during inpatient hospitalizations in the U.S., with aggregate inpatient hospital costs more than $10.5 billion.[172] Heart failure is associated with a high health expenditure, mostly because of the cost of hospitalizations; costs have been estimated to amount to 2% of the total budget of the [National Health Service](/source/National_Health_Service) in the United Kingdom, and more than $35 billion in the United States.[173][174] ## Research directions Some research indicates that [stem cell therapy](/source/Stem_cell_therapy) may help.[175] Although this research indicated benefits of stem cell therapy, other research does not indicate benefit.[176] There is tentative evidence of longer life expectancy and improved left ventricular ejection fraction in persons treated with bone marrow-derived stem cells.[175] The maintenance of heart function depends on appropriate [gene expression](/source/Gene_expression) that is regulated at multiple levels by [epignetic mechanisms](/source/Epigenetics) including [DNA methylation](/source/DNA_methylation) and [histone post-translational modification](/source/Histone-modifying_enzymes).[177][178] Currently, an increasing body of research is directed at understanding the role of perturbations of epigenetic processes in [cardiac hypertrophy](/source/Hypertrophic_cardiomyopathy) and [fibrotic scarring](/source/Fibrosis).[177][178] ## Notes 1. **[^](#cite_ref-112)** Specifically, in one randomized control trial the patients self-identified as black (defined as of African descent), and in one randomized control trial the patients were defined as *black*, without further details given.[111] ## References 1. **[^](#cite_ref-1)** Harrison RN, Daly L (2011). [*A Nurse's Survival Guide to Acute Medical Emergencies*](https://books.google.com/books?id=Uk7wbaUWDRYC&pg=PA26). Elsevier Health Sciences. p. 26. [ISBN](/source/ISBN_(identifier)) [978-0-7020-4900-2](https://en.wikipedia.org/wiki/Special:BookSources/978-0-7020-4900-2). [Archived](https://web.archive.org/web/20230809061722/https://books.google.com/books?id=Uk7wbaUWDRYC&pg=PA26) from the original on 9 August 2023. Retrieved 25 August 2020. 1. **[^](#cite_ref-2)** ["Congestive heart failure (CHF)"](https://www.betterhealth.vic.gov.au/health/conditionsandtreatments/congestive-heart-failure-chf). [Archived](https://web.archive.org/web/20160406152646/https://www.betterhealth.vic.gov.au/health/conditionsandtreatments/congestive-heart-failure-chf) from the original on 6 April 2016. Retrieved 12 November 2018. 1. ^ [***a***](#cite_ref-NICE2018ch2_3-0) [***b***](#cite_ref-NICE2018ch2_3-1) [***c***](#cite_ref-NICE2018ch2_3-2) [***d***](#cite_ref-NICE2018ch2_3-3) National Guideline Centre (UK) (September 2018). "2. Introduction". [*Chronic Heart Failure in Adults: Diagnosis and Management*](https://www.ncbi.nlm.nih.gov/books/NBK536089/). National Institute for Health and Care Excellence: Guidelines. London: National Institute for Health and Care Excellence (NICE). [ISBN](/source/ISBN_(identifier)) [978-1-4731-3093-7](https://en.wikipedia.org/wiki/Special:BookSources/978-1-4731-3093-7). [PMID](/source/PMID_(identifier)) [30645061](https://pubmed.ncbi.nlm.nih.gov/30645061). [Archived](https://web.archive.org/web/20230320160417/http://www.ncbi.nlm.nih.gov/books/NBK536089/) from the original on 20 March 2023. Retrieved 11 February 2023. 1. ^ [***a***](#cite_ref-AHA2022_4-0) [***b***](#cite_ref-AHA2022_4-1) [***c***](#cite_ref-AHA2022_4-2) [***d***](#cite_ref-AHA2022_4-3) [***e***](#cite_ref-AHA2022_4-4) [***f***](#cite_ref-AHA2022_4-5) [***g***](#cite_ref-AHA2022_4-6) [***h***](#cite_ref-AHA2022_4-7) [***i***](#cite_ref-AHA2022_4-8) [***j***](#cite_ref-AHA2022_4-9) [***k***](#cite_ref-AHA2022_4-10) Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. (May 2022). ["2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines"](https://doi.org/10.1016%2Fj.jacc.2021.12.012). *Journal of the American College of Cardiology*. **79** (17): e263–e421. [doi](/source/Doi_(identifier)):[10.1016/j.jacc.2021.12.012](https://doi.org/10.1016%2Fj.jacc.2021.12.012). [PMID](/source/PMID_(identifier)) [35379503](https://pubmed.ncbi.nlm.nih.gov/35379503). [S2CID](/source/S2CID_(identifier)) [247882156](https://api.semanticscholar.org/CorpusID:247882156). 1. **[^](#cite_ref-5)** Skipina TM, Upadhya B, Soliman EZ (July 2021). [Munafò M](/source/Marcus_Munafo) (ed.). "Secondhand Smoke Exposure is Associated with Prevalent Heart Failure: Longitudinal Examination of the National Health and Nutrition Examination Survey". *Nicotine & Tobacco Research*. **23** (9). [Oxford University Press](/source/Oxford_University_Press) on behalf of the [Society for Research on Nicotine and Tobacco](/source/Society_for_Research_on_Nicotine_and_Tobacco): 1512–1517. [doi](/source/Doi_(identifier)):[10.1093/ntr/ntab047](https://doi.org/10.1093%2Fntr%2Fntab047). [eISSN](/source/EISSN_(identifier)) [1469-994X](https://search.worldcat.org/issn/1469-994X). [LCCN](/source/LCCN_(identifier)) [00244999](https://lccn.loc.gov/00244999). [PMID](/source/PMID_(identifier)) [34213549](https://pubmed.ncbi.nlm.nih.gov/34213549). [S2CID](/source/S2CID_(identifier)) [235707832](https://api.semanticscholar.org/CorpusID:235707832). 1. ^ [***a***](#cite_ref-ESC2021_6-0) [***b***](#cite_ref-ESC2021_6-1) [***c***](#cite_ref-ESC2021_6-2) [***d***](#cite_ref-ESC2021_6-3) [***e***](#cite_ref-ESC2021_6-4) [***f***](#cite_ref-ESC2021_6-5) [***g***](#cite_ref-ESC2021_6-6) [***h***](#cite_ref-ESC2021_6-7) [***i***](#cite_ref-ESC2021_6-8) [***j***](#cite_ref-ESC2021_6-9) [***k***](#cite_ref-ESC2021_6-10) [***l***](#cite_ref-ESC2021_6-11) [***m***](#cite_ref-ESC2021_6-12) [***n***](#cite_ref-ESC2021_6-13) [***o***](#cite_ref-ESC2021_6-14) [***p***](#cite_ref-ESC2021_6-15) [***q***](#cite_ref-ESC2021_6-16) [***r***](#cite_ref-ESC2021_6-17) [***s***](#cite_ref-ESC2021_6-18) [***t***](#cite_ref-ESC2021_6-19) [***u***](#cite_ref-ESC2021_6-20) McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. (September 2021). ["2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure"](https://academic.oup.com/eurheartj/article-pdf/42/36/3599/40594787/ehab368.pdf) (PDF). *European Heart Journal*. **42** (36): 3599–3726. [doi](/source/Doi_(identifier)):[10.1093/eurheartj/ehab368](https://doi.org/10.1093%2Feurheartj%2Fehab368). [PMID](/source/PMID_(identifier)) [34447992](https://pubmed.ncbi.nlm.nih.gov/34447992). [Archived](https://web.archive.org/web/20220908043625/https://academic.oup.com/eurheartj/article-pdf/42/36/3599/40594787/ehab368.pdf) (PDF) from the original on 8 September 2022. Retrieved 7 February 2023. 1. ^ [***a***](#cite_ref-NICE2010chp4_7-0) [***b***](#cite_ref-NICE2010chp4_7-1) [***c***](#cite_ref-NICE2010chp4_7-2) *Chronic Heart Failure: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care: Partial Update*. National Clinical Guideline Centre. August 2010. pp. 38–70. [PMID](/source/PMID_(identifier)) [22741186](https://pubmed.ncbi.nlm.nih.gov/22741186). 1. ^ [***a***](#cite_ref-GBD2015Pre_8-0) [***b***](#cite_ref-GBD2015Pre_8-1) GBD 2015 Disease and Injury Incidence and Prevalence Collaborators (October 2016). ["Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055577). *Lancet*. **388** (10053): 1545–1602. [doi](/source/Doi_(identifier)):[10.1016/S0140-6736(16)31678-6](https://doi.org/10.1016%2FS0140-6736%2816%2931678-6). [PMC](/source/PMC_(identifier)) [5055577](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055577). [PMID](/source/PMID_(identifier)) [27733282](https://pubmed.ncbi.nlm.nih.gov/27733282). 1. ^ [***a***](#cite_ref-Lancet2005_9-0) [***b***](#cite_ref-Lancet2005_9-1) McMurray JJ, Pfeffer MA (2005). "Heart failure". *Lancet*. **365** (9474): 1877–89. [doi](/source/Doi_(identifier)):[10.1016/S0140-6736(05)66621-4](https://doi.org/10.1016%2FS0140-6736%2805%2966621-4). [PMID](/source/PMID_(identifier)) [15924986](https://pubmed.ncbi.nlm.nih.gov/15924986). [S2CID](/source/S2CID_(identifier)) [38678826](https://api.semanticscholar.org/CorpusID:38678826). 1. ^ [***a***](#cite_ref-NICE2010chp1_10-0) [***b***](#cite_ref-NICE2010chp1_10-1) [***c***](#cite_ref-NICE2010chp1_10-2) [***d***](#cite_ref-NICE2010chp1_10-3) [***e***](#cite_ref-NICE2010chp1_10-4) [***f***](#cite_ref-NICE2010chp1_10-5) [***g***](#cite_ref-NICE2010chp1_10-6) [***h***](#cite_ref-NICE2010chp1_10-7) [***i***](#cite_ref-NICE2010chp1_10-8) National Clinical Guideline Centre (UK) (August 2010). *Chronic heart failure: National clinical guideline for diagnosis and management in primary and secondary care: Partial update*. National Clinical Guideline Centre. pp. 19–24. [PMID](/source/PMID_(identifier)) [22741186](https://pubmed.ncbi.nlm.nih.gov/22741186). 1. **[^](#cite_ref-Akinterinwa2024_11-0)** Akinterinwa OE, Singh M, Vemuri S, Tyagi SC (August 2024). ["A Need to Preserve Ejection Fraction during Heart Failure"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11354382). *Int J Mol Sci*. **25** (16): 8780. [doi](/source/Doi_(identifier)):[10.3390/ijms25168780](https://doi.org/10.3390%2Fijms25168780). [PMC](/source/PMC_(identifier)) [11354382](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11354382). [PMID](/source/PMID_(identifier)) [39201469](https://pubmed.ncbi.nlm.nih.gov/39201469). 1. **[^](#cite_ref-HeartOrg_12-0)** ["What is Heart Failure?"](https://www.heart.org/en/health-topics/heart-failure/what-is-heart-failure). *www.heart.org*. [Archived](https://web.archive.org/web/20220810060401/https://www.heart.org/en/health-topics/heart-failure/what-is-heart-failure) from the original on 10 August 2022. Retrieved 11 August 2022. 1. **[^](#cite_ref-13)** [*Willard & Spackman's occupational therapy*](https://books.google.com/books?id=zLh3h6v5O_0C&pg=PA1124). Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins. 2014. p. 1124. [ISBN](/source/ISBN_(identifier)) [978-1-4511-1080-7](https://en.wikipedia.org/wiki/Special:BookSources/978-1-4511-1080-7). 1. **[^](#cite_ref-14)** [*The Cardiac Care Unit Survival Guide*](https://books.google.com/books?id=ZvkUJZCoi2EC&pg=PA98). Lippincott Williams & Wilkins. 2012. p. 98. [ISBN](/source/ISBN_(identifier)) [978-1-4511-7746-6](https://en.wikipedia.org/wiki/Special:BookSources/978-1-4511-7746-6). 1. ^ [***a***](#cite_ref-NICE2018ch1_15-0) [***b***](#cite_ref-NICE2018ch1_15-1) National Guideline Centre (UK) (September 2018). "1. Guideline summary". [*Chronic Heart Failure in Adults: Diagnosis and Management*](https://www.ncbi.nlm.nih.gov/books/NBK536098/). National Institute for Health and Care Excellence: Guidelines. London: National Institute for Health and Care Excellence (NICE). [ISBN](/source/ISBN_(identifier)) [978-1-4731-3093-7](https://en.wikipedia.org/wiki/Special:BookSources/978-1-4731-3093-7). [PMID](/source/PMID_(identifier)) [30645061](https://pubmed.ncbi.nlm.nih.gov/30645061). [Archived](https://web.archive.org/web/20230320152908/http://www.ncbi.nlm.nih.gov/books/NBK536098/) from the original on 20 March 2023. Retrieved 11 February 2023. 1. ^ [***a***](#cite_ref-NICE2010chp3_16-0) [***b***](#cite_ref-NICE2010chp3_16-1) *Chronic Heart Failure: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care: Partial Update*. National Clinical Guideline Centre. August 2010. pp. 34–47. [PMID](/source/PMID_(identifier)) [22741186](https://pubmed.ncbi.nlm.nih.gov/22741186). 1. ^ [***a***](#cite_ref-NICE2018ch6_17-0) [***b***](#cite_ref-NICE2018ch6_17-1) [***c***](#cite_ref-NICE2018ch6_17-2) National Guideline Centre (UK) (September 2018). "6. Treating heart failure". [*Chronic Heart Failure in Adults: Diagnosis and Management*](https://www.ncbi.nlm.nih.gov/books/NBK536070/). National Institute for Health and Care Excellence: Guidelines. London: National Institute for Health and Care Excellence (NICE). [ISBN](/source/ISBN_(identifier)) [978-1-4731-3093-7](https://en.wikipedia.org/wiki/Special:BookSources/978-1-4731-3093-7). [PMID](/source/PMID_(identifier)) [30645061](https://pubmed.ncbi.nlm.nih.gov/30645061). [Archived](https://web.archive.org/web/20230319162359/http://www.ncbi.nlm.nih.gov/books/NBK536070/) from the original on 19 March 2023. Retrieved 12 February 2023. 1. **[^](#cite_ref-NICE2018ch7_18-0)** National Guideline Centre (UK) (September 2018). "7. Rehabilitation in chronic heart failure". [*Chronic Heart Failure in Adults: Diagnosis and Management*](https://www.ncbi.nlm.nih.gov/books/NBK536079/). National Institute for Health and Care Excellence: Guidelines. London: National Institute for Health and Care Excellence (NICE). [ISBN](/source/ISBN_(identifier)) [978-1-4731-3093-7](https://en.wikipedia.org/wiki/Special:BookSources/978-1-4731-3093-7). [PMID](/source/PMID_(identifier)) [30645061](https://pubmed.ncbi.nlm.nih.gov/30645061). [Archived](https://web.archive.org/web/20230321013541/http://www.ncbi.nlm.nih.gov/books/NBK536079/) from the original on 21 March 2023. Retrieved 12 February 2023. 1. ^ [***a***](#cite_ref-:0_19-0) [***b***](#cite_ref-:0_19-1) Molloy C, Long L, Mordi IR, Bridges C, Sagar VA, Davies EJ, et al. (March 2024). ["Exercise-based cardiac rehabilitation for adults with heart failure"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10919451). *The Cochrane Database of Systematic Reviews*. **2024** (3) CD003331. [doi](/source/Doi_(identifier)):[10.1002/14651858.CD003331.pub6](https://doi.org/10.1002%2F14651858.CD003331.pub6). [PMC](/source/PMC_(identifier)) [10919451](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10919451). [PMID](/source/PMID_(identifier)) [38451843](https://pubmed.ncbi.nlm.nih.gov/38451843). 1. ^ [***a***](#cite_ref-NICE2010chp5_20-0) [***b***](#cite_ref-NICE2010chp5_20-1) *Chronic Heart Failure: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care: Partial Update*. National Clinical Guideline Centre. August 2010. pp. 71–153. [PMID](/source/PMID_(identifier)) [22741186](https://pubmed.ncbi.nlm.nih.gov/22741186). 1. ^ [***a***](#cite_ref-Guidelines_rhythm-abnormalities_21-0) [***b***](#cite_ref-Guidelines_rhythm-abnormalities_21-1) [***c***](#cite_ref-Guidelines_rhythm-abnormalities_21-2) Tracy CM, Epstein AE, Darbar D, DiMarco JP, Dunbar SB, Estes NA, et al. (October 2012). ["2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. \[corrected\]"](https://doi.org/10.1161%2FCIR.0b013e3182618569). *Circulation*. **126** (14): 1784–800. [doi](/source/Doi_(identifier)):[10.1161/CIR.0b013e3182618569](https://doi.org/10.1161%2FCIR.0b013e3182618569). [PMID](/source/PMID_(identifier)) [22965336](https://pubmed.ncbi.nlm.nih.gov/22965336). 1. ^ [***a***](#cite_ref-Kuck_2013_22-0) [***b***](#cite_ref-Kuck_2013_22-1) [***c***](#cite_ref-Kuck_2013_22-2) Kuck KH, Bordachar P, Borggrefe M, Boriani G, Burri H, Leyva F, et al. (January 2014). ["New devices in heart failure: a European Heart Rhythm Association report: developed by the European Heart Rhythm Association; endorsed by the Heart Failure Association"](https://doi.org/10.1093%2Feuropace%2Feut311). *Europace*. **16** (1): 109–28. [doi](/source/Doi_(identifier)):[10.1093/europace/eut311](https://doi.org/10.1093%2Feuropace%2Feut311). [hdl](/source/Hdl_(identifier)):[11380/1139694](https://hdl.handle.net/11380%2F1139694). [PMID](/source/PMID_(identifier)) [24265466](https://pubmed.ncbi.nlm.nih.gov/24265466). 1. ^ [***a***](#cite_ref-Lancet2017_23-0) [***b***](#cite_ref-Lancet2017_23-1) [***c***](#cite_ref-Lancet2017_23-2) [***d***](#cite_ref-Lancet2017_23-3) [***e***](#cite_ref-Lancet2017_23-4) [***f***](#cite_ref-Lancet2017_23-5) [***g***](#cite_ref-Lancet2017_23-6) Metra M, Teerlink JR (October 2017). "Heart failure". *Lancet*. **390** (10106): 1981–1995. [doi](/source/Doi_(identifier)):[10.1016/S0140-6736(17)31071-1](https://doi.org/10.1016%2FS0140-6736%2817%2931071-1). [PMID](/source/PMID_(identifier)) [28460827](https://pubmed.ncbi.nlm.nih.gov/28460827). [S2CID](/source/S2CID_(identifier)) [34893221](https://api.semanticscholar.org/CorpusID:34893221). 1. **[^](#cite_ref-24)** Retrum JH, Boggs J, Hersh A, Wright L, Main DS, Magid DJ, et al. (March 2013). ["Patient-identified factors related to heart failure readmissions"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4082819). *Circulation: Cardiovascular Quality and Outcomes*. **6** (2): 171–177. [doi](/source/Doi_(identifier)):[10.1161/CIRCOUTCOMES.112.967356](https://doi.org/10.1161%2FCIRCOUTCOMES.112.967356). [PMC](/source/PMC_(identifier)) [4082819](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4082819). [PMID](/source/PMID_(identifier)) [23386663](https://pubmed.ncbi.nlm.nih.gov/23386663). 1. **[^](#cite_ref-25)** Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. (January 2012). ["Heart disease and stroke statistics--2012 update: a report from the American Heart Association"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4440543). *Circulation*. **125** (1): e2–e220. [Bibcode](/source/Bibcode_(identifier)):[2012Circu.125ac046R](https://ui.adsabs.harvard.edu/abs/2012Circu.125ac046R). [doi](/source/Doi_(identifier)):[10.1161/cir.0b013e31823ac046](https://doi.org/10.1161%2Fcir.0b013e31823ac046). [PMC](/source/PMC_(identifier)) [4440543](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4440543). [PMID](/source/PMID_(identifier)) [22179539](https://pubmed.ncbi.nlm.nih.gov/22179539). 1. **[^](#cite_ref-26)** ["Do we expect the body to be a "One Hoss Shay"?"](https://evmedreview.com/do-we-expect-the-body-to-be-a-one-hoss-shay/). *The Evolution and Medicine Review*. 16 March 2010. [Archived](https://web.archive.org/web/20220704213458/https://evmedreview.com/do-we-expect-the-body-to-be-a-one-hoss-shay/) from the original on 4 July 2022. Retrieved 28 April 2022. 1. **[^](#cite_ref-McD2011_27-0)** McDonagh TA (2011). [*Oxford textbook of heart failure*](https://books.google.com/books?id=r8wowXxC1voC&pg=PP1). Oxford: Oxford University Press. p. 3. [ISBN](/source/ISBN_(identifier)) [978-0-19-957772-9](https://en.wikipedia.org/wiki/Special:BookSources/978-0-19-957772-9). [Archived](https://web.archive.org/web/20230809061722/https://books.google.com/books?id=r8wowXxC1voC&pg=PP1) from the original on 9 August 2023. Retrieved 27 December 2021. 1. **[^](#cite_ref-Girerd2018_28-0)** Girerd N, Seronde MF, Coiro S, Chouihed T, Bilbault P, Braun F, et al. (2018). "Integrative Assessment of Congestion in Heart Failure Throughout the Patient Journey". *JACC Heart Fail*. **6** (4): 273–285. [doi](/source/Doi_(identifier)):[10.1016/j.jchf.2017.09.023](https://doi.org/10.1016%2Fj.jchf.2017.09.023). [PMID](/source/PMID_(identifier)) [29226815](https://pubmed.ncbi.nlm.nih.gov/29226815). 1. ^ [***a***](#cite_ref-Thibodeau2018_29-0) [***b***](#cite_ref-Thibodeau2018_29-1) Thibodeau JT, Drazner MH (July 2018). ["The Role of the Clinical Examination in Patients With Heart Failure"](https://doi.org/10.1016%2Fj.jchf.2018.04.005). *JACC. Heart Failure*. **6** (7): 543–551. [doi](/source/Doi_(identifier)):[10.1016/j.jchf.2018.04.005](https://doi.org/10.1016%2Fj.jchf.2018.04.005). [PMID](/source/PMID_(identifier)) [29885957](https://pubmed.ncbi.nlm.nih.gov/29885957). 1. **[^](#cite_ref-Cleveland_Clinic_2021_30-0)** ["Pulse pressure"](https://my.clevelandclinic.org/health/symptoms/21629-pulse-pressure). Cleveland Clinic. 28 July 2021. [Archived](https://web.archive.org/web/20230210055608/https://my.clevelandclinic.org/health/symptoms/21629-pulse-pressure) from the original on 10 February 2023. Retrieved 10 February 2023. A narrow pulse pressure — sometimes called a low pulse pressure — is where your pulse pressure is one-fourth or less of your systolic pressure (the top number). This happens when your heart isn't pumping enough blood, which is seen in heart failure and certain heart valve diseases. 1. ^ [***a***](#cite_ref-IQWiG2018_31-0) [***b***](#cite_ref-IQWiG2018_31-1) [*Types of heart failure*](https://www.ncbi.nlm.nih.gov/books/NBK481485/). Institute for Quality and Efficiency in Health Care (IQWiG). 25 January 2018. [Archived](https://web.archive.org/web/20210220140029/https://www.ncbi.nlm.nih.gov/books/NBK481485/) from the original on 20 February 2021. Retrieved 9 August 2021 – via National Center for Biotechnology Information, U.S. National Library of Medicine. 1. **[^](#cite_ref-32)** Adeyinka A, Kondamudi NP (2022). ["Cyanosis"](https://www.ncbi.nlm.nih.gov/books/NBK482247/). *StatPearls*. Treasure Island (FL): StatPearls Publishing. [PMID](/source/PMID_(identifier)) [29489181](https://pubmed.ncbi.nlm.nih.gov/29489181). [Archived](https://web.archive.org/web/20210313021701/https://www.ncbi.nlm.nih.gov/books/NBK482247/) from the original on 13 March 2021. Retrieved 11 May 2022. 1. **[^](#cite_ref-33)** ["Heart Murmur: Types & Causes"](https://my.clevelandclinic.org/health/diseases/17083-heart-murmur). *Cleveland Clinic*. [Archived](https://web.archive.org/web/20221128033026/https://my.clevelandclinic.org/health/diseases/17083-heart-murmur) from the original on 28 November 2022. Retrieved 11 May 2022. 1. **[^](#cite_ref-34)** ["What is Exercise Intolerance?"](https://www.webmd.com/fitness-exercise/what-to-know-about-exercise-intolerance). *WebMD*. [Archived](https://web.archive.org/web/20220511094156/https://www.webmd.com/fitness-exercise/what-to-know-about-exercise-intolerance) from the original on 11 May 2022. Retrieved 11 May 2022. 1. **[^](#cite_ref-35)** ["Heart Failure Signs and Symptoms"](https://www.heart.org/en/health-topics/heart-failure/warning-signs-of-heart-failure). *heart.org*. American Heart Association. [Archived](https://web.archive.org/web/20221117045606/https://www.heart.org/en/health-topics/heart-failure/warning-signs-of-heart-failure) from the original on 17 November 2022. Retrieved 16 November 2022. 1. **[^](#cite_ref-ESC2016_36-0)** Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. (14 July 2016). ["2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC"](https://academic.oup.com/eurheartj/article-pdf/37/27/2129/23748755/ehw128.pdf) (PDF). *European Journal of Heart Failure* (Review). **37** (27): 2129–2200. [doi](/source/Doi_(identifier)):[10.1093/eurheartj/ehw128](https://doi.org/10.1093%2Feurheartj%2Fehw128). [hdl](/source/Hdl_(identifier)):[2434/427148](https://hdl.handle.net/2434%2F427148). [PMID](/source/PMID_(identifier)) [27207191](https://pubmed.ncbi.nlm.nih.gov/27207191). [S2CID](/source/S2CID_(identifier)) [221675744](https://api.semanticscholar.org/CorpusID:221675744). [Archived](https://web.archive.org/web/20230207205925/https://academic.oup.com/eurheartj/article-pdf/37/27/2129/23748755/ehw128.pdf) (PDF) from the original on 7 February 2023. Retrieved 7 February 2023. 1. **[^](#cite_ref-37)** Alcantara CA, Chandra A, Morvey D, von Schwarz ER (3 January 2018). "Acute Right Heart Failure". *Right Heart Pathology*. pp. 215–225. [doi](/source/Doi_(identifier)):[10.1007/978-3-319-73764-5_10](https://doi.org/10.1007%2F978-3-319-73764-5_10). [ISBN](/source/ISBN_(identifier)) [978-3-319-73763-8](https://en.wikipedia.org/wiki/Special:BookSources/978-3-319-73763-8). [PMC](/source/PMC_(identifier)) [7123149](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123149). 1. **[^](#cite_ref-pmid26350935_38-0)** Bhatnagar R, Maskell N (September 2015). ["The modern diagnosis and management of pleural effusions"](https://research-information.bris.ac.uk/en/publications/deeb861e-d752-4e4c-a8d7-f00cc22eddac). *BMJ*. **351** h4520. [doi](/source/Doi_(identifier)):[10.1136/bmj.h4520](https://doi.org/10.1136%2Fbmj.h4520). [hdl](/source/Hdl_(identifier)):[1983/deeb861e-d752-4e4c-a8d7-f00cc22eddac](https://hdl.handle.net/1983%2Fdeeb861e-d752-4e4c-a8d7-f00cc22eddac). [PMID](/source/PMID_(identifier)) [26350935](https://pubmed.ncbi.nlm.nih.gov/26350935). [S2CID](/source/S2CID_(identifier)) [1883969](https://api.semanticscholar.org/CorpusID:1883969). [Archived](https://web.archive.org/web/20230809061730/https://research-information.bris.ac.uk/en/publications/the-modern-diagnosis-and-management-of-pleural-effusions) from the original on 9 August 2023. Retrieved 13 February 2023. 1. **[^](#cite_ref-39)** Sayer G, Semigran MJ (22 February 2017). "Acute and Chronic Right Ventricular Failure". In Eisen H (ed.). *Heart Failure Heart: A Comprehensive Guide to Pathophysiology and Clinical Care*. Vol. 6. pp. 65–84. [doi](/source/Doi_(identifier)):[10.1007/978-1-4471-4219-5_4](https://doi.org/10.1007%2F978-1-4471-4219-5_4). [ISBN](/source/ISBN_(identifier)) [978-1-4471-4218-8](https://en.wikipedia.org/wiki/Special:BookSources/978-1-4471-4218-8). [PMC](/source/PMC_(identifier)) [7122716](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7122716). [PMID](/source/PMID_(identifier)) [29226816](https://pubmed.ncbi.nlm.nih.gov/29226816). 1. **[^](#cite_ref-FOOTNOTEPonikowskiVoorsAnkerBueno20162136_40-0)** [Ponikowski et al. 2016](#CITEREFPonikowskiVoorsAnkerBueno2016), p. 2136. 1. ^ [***a***](#cite_ref-Davis_2000_41-0) [***b***](#cite_ref-Davis_2000_41-1) [***c***](#cite_ref-Davis_2000_41-2) [***d***](#cite_ref-Davis_2000_41-3) [***e***](#cite_ref-Davis_2000_41-4) Davis RC, Hobbs FD, Lip GY (January 2000). ["ABC of heart failure. History and epidemiology"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1117316). *BMJ*. **320** (7226): 39–42. [doi](/source/Doi_(identifier)):[10.1136/bmj.320.7226.39](https://doi.org/10.1136%2Fbmj.320.7226.39). [PMC](/source/PMC_(identifier)) [1117316](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1117316). [PMID](/source/PMID_(identifier)) [10617530](https://pubmed.ncbi.nlm.nih.gov/10617530). 1. **[^](#cite_ref-42)** Hazebroek MR, Moors S, Dennert R, van den Wijngaard A, Krapels I, Hoos M, et al. (September 2015). ["Prognostic Relevance of Gene-Environment Interactions in Patients With Dilated Cardiomyopathy: Applying the MOGE(S) Classification"](https://doi.org/10.1016%2Fj.jacc.2015.07.023). *Journal of the American College of Cardiology*. **66** (12): 1313–23. [doi](/source/Doi_(identifier)):[10.1016/j.jacc.2015.07.023](https://doi.org/10.1016%2Fj.jacc.2015.07.023). [PMID](/source/PMID_(identifier)) [26383716](https://pubmed.ncbi.nlm.nih.gov/26383716). 1. **[^](#cite_ref-43)** Khattak HK, Hayat F, Pamboukian SV, Hahn HS, Schwartz BP, Stein PK (June 2018). ["Obstructive Sleep Apnea in Heart Failure: Review of Prevalence, Treatment with Continuous Positive Airway Pressure, and Prognosis"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059510). *Texas Heart Institute Journal*. **45** (3): 151–161. [doi](/source/Doi_(identifier)):[10.14503/THIJ-15-5678](https://doi.org/10.14503%2FTHIJ-15-5678). [PMC](/source/PMC_(identifier)) [6059510](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059510). [PMID](/source/PMID_(identifier)) [30072851](https://pubmed.ncbi.nlm.nih.gov/30072851). 1. **[^](#cite_ref-44)** Muntner P, Whittle J, Lynch AI, Colantonio LD, Simpson LM, Einhorn PT, et al. (September 2015). ["Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality: A Cohort Study"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5021508). *Annals of Internal Medicine*. **163** (5): 329–38. [doi](/source/Doi_(identifier)):[10.7326/M14-2803](https://doi.org/10.7326%2FM14-2803). [PMC](/source/PMC_(identifier)) [5021508](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5021508). [PMID](/source/PMID_(identifier)) [26215765](https://pubmed.ncbi.nlm.nih.gov/26215765). 1. **[^](#cite_ref-45)** Nuyujukian DS, Koska J, Bahn G, Reaven PD, Zhou JJ (July 2020). ["Blood Pressure Variability and Risk of Heart Failure in ACCORD and the VADT"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305004). *Diabetes Care*. **43** (7): 1471–1478. [doi](/source/Doi_(identifier)):[10.2337/dc19-2540](https://doi.org/10.2337%2Fdc19-2540). [hdl](/source/Hdl_(identifier)):[10150/641980](https://hdl.handle.net/10150%2F641980). [PMC](/source/PMC_(identifier)) [7305004](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305004). [PMID](/source/PMID_(identifier)) [32327422](https://pubmed.ncbi.nlm.nih.gov/32327422). 1. **[^](#cite_ref-46)** Nwabuo CC, Yano Y, Moreira HT, Appiah D, Vasconcellos HD, Aghaji QN, et al. (July 2020). ["Association Between Visit-to-Visit Blood Pressure Variability in Early Adulthood and Myocardial Structure and Function in Later Life"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160747). *JAMA Cardiology*. **5** (7): 795–801. [doi](/source/Doi_(identifier)):[10.1001/jamacardio.2020.0799](https://doi.org/10.1001%2Fjamacardio.2020.0799). [PMC](/source/PMC_(identifier)) [7160747](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160747). [PMID](/source/PMID_(identifier)) [32293640](https://pubmed.ncbi.nlm.nih.gov/32293640). 1. ^ [***a***](#cite_ref-ReferenceA_47-0) [***b***](#cite_ref-ReferenceA_47-1) ["high-output heart failure"](https://web.archive.org/web/20090628224336/http://www.mercksource.com/pp/us/cns/cns_hl_dorlands_split.jsp?pg=/ppdocs/us/common/dorlands/dorland/nine/000953450.htm) at *[Dorland's Medical Dictionary](/source/Dorland's_medical_reference_works)* 1. **[^](#cite_ref-pmid26567494_48-0)** McCulloch B (December 2015). "High-Output Heart Failure Caused by Thyrotoxicosis and Beriberi". *Crit Care Nurs Clin North Am*. **27** (4): 499–510. [doi](/source/Doi_(identifier)):[10.1016/j.cnc.2015.07.004](https://doi.org/10.1016%2Fj.cnc.2015.07.004). [PMID](/source/PMID_(identifier)) [26567494](https://pubmed.ncbi.nlm.nih.gov/26567494). 1. **[^](#cite_ref-Carlisi_49-0)** Carlisi M, Mancuso S, Lo Presti R, Siragusa S, Caimi G (January 2022). ["High Output Heart Failure in Multiple Myeloma: Pathogenetic Considerations"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833382). *Cancers (Basel)*. **14** (3): 610. [doi](/source/Doi_(identifier)):[10.3390/cancers14030610](https://doi.org/10.3390%2Fcancers14030610). [PMC](/source/PMC_(identifier)) [8833382](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833382). [PMID](/source/PMID_(identifier)) [35158878](https://pubmed.ncbi.nlm.nih.gov/35158878). 1. **[^](#cite_ref-OPTIMIZE-HF_50-0)** Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al. (April 2008). "Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF". *Archives of Internal Medicine*. **168** (8): 847–54. [doi](/source/Doi_(identifier)):[10.1001/archinte.168.8.847](https://doi.org/10.1001%2Farchinte.168.8.847). [PMID](/source/PMID_(identifier)) [18443260](https://pubmed.ncbi.nlm.nih.gov/18443260). [S2CID](/source/S2CID_(identifier)) [20912905](https://api.semanticscholar.org/CorpusID:20912905). 1. **[^](#cite_ref-51)** Nieminen MS, Böhm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G, et al. (February 2005). ["Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology"](http://repositorio.chporto.pt/bitstream/10400.16/493/1/pdf.4.pdf) (PDF). *European Heart Journal*. **26** (4): 384–416. [doi](/source/Doi_(identifier)):[10.1093/eurheartj/ehi044](https://doi.org/10.1093%2Feurheartj%2Fehi044). [PMID](/source/PMID_(identifier)) [15681577](https://pubmed.ncbi.nlm.nih.gov/15681577). [Archived](https://web.archive.org/web/20170810020623/http://repositorio.chporto.pt/bitstream/10400.16/493/1/pdf.4.pdf) (PDF) from the original on 10 August 2017. Retrieved 18 September 2019. 1. **[^](#cite_ref-52)** Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, et al. (August 2013). ["Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3778977). *Lancet*. **382** (9894): 769–79. [doi](/source/Doi_(identifier)):[10.1016/S0140-6736(13)60900-9](https://doi.org/10.1016%2FS0140-6736%2813%2960900-9). [PMC](/source/PMC_(identifier)) [3778977](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3778977). [PMID](/source/PMID_(identifier)) [23726390](https://pubmed.ncbi.nlm.nih.gov/23726390). 1. **[^](#cite_ref-pmid30165516_53-0)** Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. (2018). ["2018 ESC/ESH Guidelines for the management of arterial hypertension"](https://doi.org/10.1093%2Feurheartj%2Fehy339). *European Heart Journal*. **39** (33): 3021–3104. [doi](/source/Doi_(identifier)):[10.1093/eurheartj/ehy339](https://doi.org/10.1093%2Feurheartj%2Fehy339). [PMID](/source/PMID_(identifier)) [30165516](https://pubmed.ncbi.nlm.nih.gov/30165516). 1. **[^](#cite_ref-pmid31668726_54-0)** Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen R, Pratt N, et al. (2019). ["Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6924620). *Lancet*. **394** (10211): 1816–1826. [doi](/source/Doi_(identifier)):[10.1016/S0140-6736(19)32317-7](https://doi.org/10.1016%2FS0140-6736%2819%2932317-7). [PMC](/source/PMC_(identifier)) [6924620](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6924620). [PMID](/source/PMID_(identifier)) [31668726](https://pubmed.ncbi.nlm.nih.gov/31668726). 1. ^ [***a***](#cite_ref-PageAHA_55-0) [***b***](#cite_ref-PageAHA_55-1) [***c***](#cite_ref-PageAHA_55-2) [***d***](#cite_ref-PageAHA_55-3) [***e***](#cite_ref-PageAHA_55-4) [***f***](#cite_ref-PageAHA_55-5) [***g***](#cite_ref-PageAHA_55-6) [***h***](#cite_ref-PageAHA_55-7) [***i***](#cite_ref-PageAHA_55-8) [***j***](#cite_ref-PageAHA_55-9) Page RL, O'Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM, et al. (August 2016). ["Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association"](https://doi.org/10.1161%2FCIR.0000000000000426). *Circulation*. **134** (6): e32–69. [doi](/source/Doi_(identifier)):[10.1161/CIR.0000000000000426](https://doi.org/10.1161%2FCIR.0000000000000426). [PMID](/source/PMID_(identifier)) [27400984](https://pubmed.ncbi.nlm.nih.gov/27400984). 1. **[^](#cite_ref-56)** Lenneman CG, Sawyer DB (March 2016). "Cardio-Oncology: An Update on Cardiotoxicity of Cancer-Related Treatment". *Circulation Research*. **118** (6): 1008–1020. [doi](/source/Doi_(identifier)):[10.1161/CIRCRESAHA.115.303633](https://doi.org/10.1161%2FCIRCRESAHA.115.303633). [PMID](/source/PMID_(identifier)) [26987914](https://pubmed.ncbi.nlm.nih.gov/26987914). 1. ^ [***a***](#cite_ref-Galimzhanov_2003_57-0) [***b***](#cite_ref-Galimzhanov_2003_57-1) Galimzhanov A, Istanbuly S, Tun HN, Ozbay B, Alasnag M, Ky B, et al. (December 2023). ["Cardiovascular outcomes in breast cancer survivors: a systematic review and meta-analysis"](https://doi.org/10.1093%2Feurjpc%2Fzwad243). *European Journal of Preventive Cardiology*. **30** (18): 2018–2031. [doi](/source/Doi_(identifier)):[10.1093/eurjpc/zwad243](https://doi.org/10.1093%2Feurjpc%2Fzwad243). [PMID](/source/PMID_(identifier)) [37499186](https://pubmed.ncbi.nlm.nih.gov/37499186). 1. **[^](#cite_ref-58)** Boron WF, Boulpaep EL (2005). *Medical Physiology: A Cellular and Molecular Approach* (updated ed.). Saunders. p. 533. [ISBN](/source/ISBN_(identifier)) [978-0-7216-3256-8](https://en.wikipedia.org/wiki/Special:BookSources/978-0-7216-3256-8). 1. ^ [***a***](#cite_ref-HFA2019_59-0) [***b***](#cite_ref-HFA2019_59-1) Pieske B, Tschöpe C, de Boer RA, Fraser AG, Anker SD, Donal E, et al. (October 2019). ["How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)"](https://academic.oup.com/eurheartj/article/40/40/3297/5557740). *European Heart Journal*. **40** (40): 3297–3317. [doi](/source/Doi_(identifier)):[10.1093/eurheartj/ehz641](https://doi.org/10.1093%2Feurheartj%2Fehz641). [PMID](/source/PMID_(identifier)) [31504452](https://pubmed.ncbi.nlm.nih.gov/31504452). [Archived](https://web.archive.org/web/20230220182959/https://academic.oup.com/eurheartj/article/40/40/3297/5557740) from the original on 20 February 2023. Retrieved 20 February 2023. 1. **[^](#cite_ref-60)** ["Heart Failure: Signs and Symptoms"](http://www.ucsfhealth.org/conditions/heart_failure/signs_and_symptoms.html). UCSF Medical Center. [Archived](https://web.archive.org/web/20140407080141/http://www.ucsfhealth.org/conditions/heart_failure/signs_and_symptoms.html) from the original on 7 April 2014. 1. ^ [***a***](#cite_ref-HRS2014_61-0) [***b***](#cite_ref-HRS2014_61-1) ["Ejection Fraction"](http://www.hrsonline.org/Patient-Resources/The-Normal-Heart/Ejection-Fraction#axzz31jSSC7Uo). *Heart Rhythm Society*. [Archived](https://web.archive.org/web/20140502123346/http://www.hrsonline.org/Patient-Resources/The-Normal-Heart/Ejection-Fraction#axzz31jSSC7Uo) from the original on 2 May 2014. Retrieved 7 June 2014. 1. **[^](#cite_ref-pmid35460242_62-0)** Santulli G, Wang X, Mone P (August 2022). ["Updated ACC/AHA/HFSA 2022 guidelines on heart failure: what is new? From epidemiology to clinical management"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366633). *Eur Heart J Cardiovasc Pharmacother*. **8** (5): e23–e24. [doi](/source/Doi_(identifier)):[10.1093/ehjcvp/pvac029](https://doi.org/10.1093%2Fehjcvp%2Fpvac029). [PMC](/source/PMC_(identifier)) [9366633](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366633). [PMID](/source/PMID_(identifier)) [35460242](https://pubmed.ncbi.nlm.nih.gov/35460242). 1. **[^](#cite_ref-63)** ["Ejection Fraction Heart Failure Measurement"](http://www.heart.org/HEARTORG/Conditions/HeartFailure/SymptomsDiagnosisofHeartFailure/Ejection-Fraction-Heart-Failure-Measurement_UCM_306339_Article.jsp). *American Heart Association*. 11 February 2014. [Archived](https://web.archive.org/web/20140714140152/http://www.heart.org/HEARTORG/Conditions/HeartFailure/SymptomsDiagnosisofHeartFailure/Ejection-Fraction-Heart-Failure-Measurement_UCM_306339_Article.jsp) from the original on 14 July 2014. Retrieved 7 June 2014. 1. ^ [***a***](#cite_ref-HFmrEF_ESC2021_64-0) [***b***](#cite_ref-HFmrEF_ESC2021_64-1) ["2021 ESC Clinical Practice Guidelines for the diagnosis and treatment of acute and chronic heart failure"](https://www.escardio.org/Congresses-Events/ESC-Congress/Congress-resources/Congress-news/2021-esc-clinical-practice-guidelines-for-the-diagnosis-and-treatment-of-acute-a). *European Society of Cardiology*. 27 August 2021. [Archived](https://web.archive.org/web/20230206211913/https://www.escardio.org/Congresses-Events/ESC-Congress/Congress-resources/Congress-news/2021-esc-clinical-practice-guidelines-for-the-diagnosis-and-treatment-of-acute-a) from the original on 6 February 2023. Retrieved 6 February 2023. 1. **[^](#cite_ref-65)** Bozkurt B, Hershberger RE, Butler J, Grady KL, Heidenreich PA, Isler ML, et al. (April 2021). ["2021 ACC/AHA Key Data Elements and Definitions for Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Heart Failure)"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8059763). *Circulation: Cardiovascular Quality and Outcomes*. **14** (4) e000102. [doi](/source/Doi_(identifier)):[10.1161/HCQ.0000000000000102](https://doi.org/10.1161%2FHCQ.0000000000000102). [PMC](/source/PMC_(identifier)) [8059763](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8059763). [PMID](/source/PMID_(identifier)) [33755495](https://pubmed.ncbi.nlm.nih.gov/33755495). 1. **[^](#cite_ref-66)** Devgun JK, Kennedy S, Slivnick J, Garrett Z, Dodd K, Derbala MH, et al. (February 2022). ["Heart failure with recovered ejection fraction and the utility of defibrillator therapy: a review"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787956). *ESC Heart Failure*. **9** (1): 1–10. [doi](/source/Doi_(identifier)):[10.1002/ehf2.13729](https://doi.org/10.1002%2Fehf2.13729). [PMC](/source/PMC_(identifier)) [8787956](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787956). [PMID](/source/PMID_(identifier)) [34953039](https://pubmed.ncbi.nlm.nih.gov/34953039). 1. **[^](#cite_ref-Jessup2009_67-0)** Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, et al. (April 2009). "2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation". *Circulation*. **119** (14): 1977–2016. [doi](/source/Doi_(identifier)):[10.1161/CIRCULATIONAHA.109.192064](https://doi.org/10.1161%2FCIRCULATIONAHA.109.192064). [PMID](/source/PMID_(identifier)) [19324967](https://pubmed.ncbi.nlm.nih.gov/19324967). 1. **[^](#cite_ref-pmid36356656_68-0)** Somma V, Ha FJ, Palmer S, Mohamed U, Agarwal S (October 2022). "Pacing-induced cardiomyopathy: A systematic review and meta-analysis of definition, prevalence, risk factors, and management". *Heart Rhythm*. **20** (2): 282–290. [doi](/source/Doi_(identifier)):[10.1016/j.hrthm.2022.09.019](https://doi.org/10.1016%2Fj.hrthm.2022.09.019). [PMID](/source/PMID_(identifier)) [36356656](https://pubmed.ncbi.nlm.nih.gov/36356656). [S2CID](/source/S2CID_(identifier)) [253409509](https://api.semanticscholar.org/CorpusID:253409509). 1. **[^](#cite_ref-pmid34685747_69-0)** Mages C, Gampp H, Syren P, Rahm AK, André F, Frey N, et al. (October 2021). ["Electrical Ventricular Remodeling in Dilated Cardiomyopathy"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534398). *Cells*. **10** (10): 2767. [doi](/source/Doi_(identifier)):[10.3390/cells10102767](https://doi.org/10.3390%2Fcells10102767). [PMC](/source/PMC_(identifier)) [8534398](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534398). [PMID](/source/PMID_(identifier)) [34685747](https://pubmed.ncbi.nlm.nih.gov/34685747). 1. **[^](#cite_ref-pmid30219395_70-0)** Tower-Rader A, Mohananey D, To A, Lever HM, Popovic ZB, Desai MY (October 2019). "Prognostic Value of Global Longitudinal Strain in Hypertrophic Cardiomyopathy: A Systematic Review of Existing Literature". *JACC Cardiovasc Imaging*. **12** (10): 1930–1942. [doi](/source/Doi_(identifier)):[10.1016/j.jcmg.2018.07.016](https://doi.org/10.1016%2Fj.jcmg.2018.07.016). [PMID](/source/PMID_(identifier)) [30219395](https://pubmed.ncbi.nlm.nih.gov/30219395). [S2CID](/source/S2CID_(identifier)) [52280408](https://api.semanticscholar.org/CorpusID:52280408). 1. **[^](#cite_ref-71)** Sirajuddin A, Mirmomen SM, Kligerman SJ, Groves DW, Burke AP, Kureshi F, et al. (1 July 2021). ["Ischemic Heart Disease: Noninvasive Imaging Techniques and Findings"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262179). *Radiographics*. **41** (4): 990–1021. [doi](/source/Doi_(identifier)):[10.1148/rg.2021200125](https://doi.org/10.1148%2Frg.2021200125). [PMC](/source/PMC_(identifier)) [8262179](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262179). [PMID](/source/PMID_(identifier)) [34019437](https://pubmed.ncbi.nlm.nih.gov/34019437). 1. **[^](#cite_ref-72)** Newton S (27 November 2025). ["Neck scan may find signs of heart failure in men"](https://www.pressreader.com/uk/The-i-paper/20251127/282175067414351). [The i Paper](/source/The_i_Paper). p. 29. Retrieved 27 November 2025. 1. **[^](#cite_ref-73)** Akinmolayan A, Papacosta AO, Lennon LT, Ellins EA, Halcox JP, Whincup PH, et al. (21 March 2025). ["Carotid Intima‑Media Thickness, Carotid Distensibility, and Incident Heart Failure in Older Men: The British Regional Heart Study"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12184599). *[Journal of the American Heart Association](/source/Journal_of_the_American_Heart_Association)*. **14** (7) e037167. [University College London](/source/University_College_London). [doi](/source/Doi_(identifier)):[10.1161/JAHA.124.037167](https://doi.org/10.1161%2FJAHA.124.037167). [PMC](/source/PMC_(identifier)) [12184599](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12184599). [PMID](/source/PMID_(identifier)) [40118794](https://pubmed.ncbi.nlm.nih.gov/40118794). 1. ^ [***a***](#cite_ref-UOTW48_74-0) [***b***](#cite_ref-UOTW48_74-1) [***c***](#cite_ref-UOTW48_74-2) [***d***](#cite_ref-UOTW48_74-3) [***e***](#cite_ref-UOTW48_74-4) ["UOTW #48 – Ultrasound of the Week"](https://www.ultrasoundoftheweek.com/uotw-48/). *Ultrasound of the Week*. 23 May 2015. [Archived](https://web.archive.org/web/20170509130822/https://www.ultrasoundoftheweek.com/uotw-48/) from the original on 9 May 2017. Retrieved 27 May 2017. 1. **[^](#cite_ref-75)** Al Deeb M, Barbic S, Featherstone R, Dankoff J, Barbic D (August 2014). ["Point-of-care ultrasonography for the diagnosis of acute cardiogenic pulmonary edema in patients presenting with acute dyspnea: a systematic review and meta-analysis"](https://doi.org/10.1111%2Facem.12435). *Academic Emergency Medicine*. **21** (8): 843–52. [doi](/source/Doi_(identifier)):[10.1111/acem.12435](https://doi.org/10.1111%2Facem.12435). [PMID](/source/PMID_(identifier)) [25176151](https://pubmed.ncbi.nlm.nih.gov/25176151). 1. **[^](#cite_ref-76)** Loscalzo J, Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL (2008). *Harrison's Principles of Internal Medicine* (17 ed.). McGraw-Hill Medical. p. 1447. [ISBN](/source/ISBN_(identifier)) [978-0-07-147693-5](https://en.wikipedia.org/wiki/Special:BookSources/978-0-07-147693-5). 1. **[^](#cite_ref-NICE2018ch5_77-0)** National Guideline Centre (UK) (September 2018). "5. Diagnosing heart failure". [*Chronic Heart Failure in Adults: Diagnosis and Management*](https://www.ncbi.nlm.nih.gov/books/NBK536086/). National Institute for Health and Care Excellence: Guidelines. London: National Institute for Health and Care Excellence (NICE). [ISBN](/source/ISBN_(identifier)) [978-1-4731-3093-7](https://en.wikipedia.org/wiki/Special:BookSources/978-1-4731-3093-7). [PMID](/source/PMID_(identifier)) [30645061](https://pubmed.ncbi.nlm.nih.gov/30645061). [Archived](https://web.archive.org/web/20230320112711/http://www.ncbi.nlm.nih.gov/books/NBK536086/) from the original on 20 March 2023. Retrieved 12 February 2023. 1. **[^](#cite_ref-pmid18290826_78-0)** Ewald B, Ewald D, Thakkinstian A, Attia J (February 2008). "Meta-analysis of B type natriuretic peptide and N-terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction". *Internal Medicine Journal*. **38** (2): 101–13. [doi](/source/Doi_(identifier)):[10.1111/j.1445-5994.2007.01454.x](https://doi.org/10.1111%2Fj.1445-5994.2007.01454.x). [PMID](/source/PMID_(identifier)) [18290826](https://pubmed.ncbi.nlm.nih.gov/18290826). [S2CID](/source/S2CID_(identifier)) [35294486](https://api.semanticscholar.org/CorpusID:35294486). 1. ^ [***a***](#cite_ref-US_cardiology_2008_79-0) [***b***](#cite_ref-US_cardiology_2008_79-1) [***c***](#cite_ref-US_cardiology_2008_79-2) [***d***](#cite_ref-US_cardiology_2008_79-3) Abraham WT (2008). ["Managing hyponatremia in heart failure"](https://www.uscjournal.com/articles/managing-hyponatremia-heart-failure). *US Cardiology Review*. **5** (1): 57–60. [doi](/source/Doi_(identifier)):[10.15420/usc.2008.5.1.57](https://doi.org/10.15420%2Fusc.2008.5.1.57). [Archived](https://web.archive.org/web/20211116040441/https://www.uscjournal.com/articles/managing-hyponatremia-heart-failure) from the original on 16 November 2021. Retrieved 16 January 2018. 1. **[^](#cite_ref-80)** ["Angiography – Consumer Information – InsideRadiology"](https://www.insideradiology.com.au/angiography/). *InsideRadiology*. 23 September 2016. [Archived](https://web.archive.org/web/20170822134640/https://www.insideradiology.com.au/angiography/) from the original on 22 August 2017. Retrieved 22 August 2017. 1. **[^](#cite_ref-81)** Criteria Committee, New York Heart Association (1964). *Diseases of the heart and blood vessels. Nomenclature and criteria for diagnosis* (6th ed.). Boston: Little, Brown. p. 114. 1. **[^](#cite_ref-82)** Raphael C, Briscoe C, Davies J, Ian Whinnett Z, Manisty C, Sutton R, et al. (April 2007). ["Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failure"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1861501). *Heart*. **93** (4): 476–82. [doi](/source/Doi_(identifier)):[10.1136/hrt.2006.089656](https://doi.org/10.1136%2Fhrt.2006.089656). [PMC](/source/PMC_(identifier)) [1861501](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1861501). [PMID](/source/PMID_(identifier)) [17005715](https://pubmed.ncbi.nlm.nih.gov/17005715). 1. ^ [***a***](#cite_ref-Hunt-2005_83-0) [***b***](#cite_ref-Hunt-2005_83-1) Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. (September 2005). ["ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society"](https://doi.org/10.1161%2FCIRCULATIONAHA.105.167586). *Circulation*. **112** (12): e154–235. [doi](/source/Doi_(identifier)):[10.1161/CIRCULATIONAHA.105.167586](https://doi.org/10.1161%2FCIRCULATIONAHA.105.167586). [PMID](/source/PMID_(identifier)) [16160202](https://pubmed.ncbi.nlm.nih.gov/16160202). 1. **[^](#cite_ref-84)** Majno G, Joris I (12 August 2004). [*Cells, Tissues, and Disease: Principles of General Pathology*](https://books.google.com/books?id=8yAf6U7njlcC&pg=PA620). Oxford University Press. p. 620. [ISBN](/source/ISBN_(identifier)) [978-0-19-974892-1](https://en.wikipedia.org/wiki/Special:BookSources/978-0-19-974892-1). Retrieved 19 March 2013. 1. **[^](#cite_ref-Pandey2015_85-0)** Pandey A, Garg S, Khunger M, Darden D, Ayers C, Kumbhani DJ, et al. (November 2015). ["Dose-Response Relationship Between Physical Activity and Risk of Heart Failure: A Meta-Analysis"](https://doi.org/10.1161%2FCIRCULATIONAHA.115.015853). *Circulation*. **132** (19): 1786–1794. [doi](/source/Doi_(identifier)):[10.1161/CIRCULATIONAHA.115.015853](https://doi.org/10.1161%2FCIRCULATIONAHA.115.015853). [PMID](/source/PMID_(identifier)) [26438781](https://pubmed.ncbi.nlm.nih.gov/26438781). 1. **[^](#cite_ref-86)** ["Heart Failure: Am I at Risk, and Can I Prevent It?"](https://www.webmd.com/heart-disease/heart-failure/tc/heart-failure-prevention). *Webmd*. [Archived](https://web.archive.org/web/20180330212317/https://www.webmd.com/heart-disease/heart-failure/tc/heart-failure-prevention) from the original on 30 March 2018. Retrieved 13 November 2018. 1. **[^](#cite_ref-87)** ["2019 Updated Cardiovascular Disease Prevention Guidelines Announced – Johns Hopkins Medicine"](http://clinicalconnection.hopkinsmedicine.org/news/2019-updated-cardiovascular-disease-prevention-guidelines-announced). *clinicalconnection.hopkinsmedicine.org*. 17 March 2019. [Archived](https://web.archive.org/web/20220705093722/https://clinicalconnection.hopkinsmedicine.org/news/2019-updated-cardiovascular-disease-prevention-guidelines-announced) from the original on 5 July 2022. Retrieved 29 April 2022. 1. **[^](#cite_ref-88)** Writing Group Members, Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, et al. (14 February 2006). ["Heart Disease and Stroke Statistics—2006 Update"](https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.105.171600). *Circulation*. **113** (6): e85–e151. [doi](/source/Doi_(identifier)):[10.1161/CIRCULATIONAHA.105.171600](https://doi.org/10.1161%2FCIRCULATIONAHA.105.171600). [PMID](/source/PMID_(identifier)) [16407573](https://pubmed.ncbi.nlm.nih.gov/16407573). 1. **[^](#cite_ref-89)** Bibbins-Domingo K, Lin F, Vittinghoff E (1 February 2005). ["Predictors of heart failure among women with coronary disease"](https://linkinghub.elsevier.com/retrieve/pii/S1062145804011456). *ACC Current Journal Review*. **14** (2): 35–36. [doi](/source/Doi_(identifier)):[10.1016/j.accreview.2004.12.100](https://doi.org/10.1016%2Fj.accreview.2004.12.100). [ISSN](/source/ISSN_(identifier)) [1062-1458](https://search.worldcat.org/issn/1062-1458). 1. **[^](#cite_ref-pmid33069454_90-0)** Cebeci F, Arikan B, Catal E, Bayezid O (2021). "A bridge to transplantation: The life experiences of patients with a left ventricular assist device". *Heart & Lung*. **50** (1): 106–112. [doi](/source/Doi_(identifier)):[10.1016/j.hrtlng.2020.09.020](https://doi.org/10.1016%2Fj.hrtlng.2020.09.020). [PMID](/source/PMID_(identifier)) [33069454](https://pubmed.ncbi.nlm.nih.gov/33069454). [S2CID](/source/S2CID_(identifier)) [224780668](https://api.semanticscholar.org/CorpusID:224780668). 1. **[^](#cite_ref-Pre2018_91-0)** "Acute heart failure with dyspnoea. First-choice treatments". *Prescrire International*. **27** (194): 160–162. 2018. 1. **[^](#cite_ref-92)** Man WD, Chowdhury F, Taylor RS, Evans RA, Doherty P, Singh SJ, et al. (August 2016). ["Building consensus for provision of breathlessness rehabilitation for patients with chronic obstructive pulmonary disease and chronic heart failure"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029782). *Chronic Respiratory Disease*. **13** (3): 229–39. [doi](/source/Doi_(identifier)):[10.1177/1479972316642363](https://doi.org/10.1177%2F1479972316642363). [PMC](/source/PMC_(identifier)) [5029782](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029782). [PMID](/source/PMID_(identifier)) [27072018](https://pubmed.ncbi.nlm.nih.gov/27072018). 1. **[^](#cite_ref-93)** Zhou X, Xu W, Xu Y, Qian Z (August 2019). "Iron Supplementation Improves Cardiovascular Outcomes in Patients with Heart Failure". *The American Journal of Medicine*. **132** (8): 955–963. [doi](/source/Doi_(identifier)):[10.1016/j.amjmed.2019.02.018](https://doi.org/10.1016%2Fj.amjmed.2019.02.018). [PMID](/source/PMID_(identifier)) [30853478](https://pubmed.ncbi.nlm.nih.gov/30853478). [S2CID](/source/S2CID_(identifier)) [73725232](https://api.semanticscholar.org/CorpusID:73725232). 1. ^ [***a***](#cite_ref-Nishikawa2020_94-0) [***b***](#cite_ref-Nishikawa2020_94-1) Nishikawa Y, Hiroyama N, Fukahori H, Ota E, Mizuno A, Miyashita M, et al. (Cochrane Heart Group) (February 2020). ["Advance care planning for adults with heart failure"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045766). *The Cochrane Database of Systematic Reviews*. **2020** (2) CD013022. [doi](/source/Doi_(identifier)):[10.1002/14651858.CD013022.pub2](https://doi.org/10.1002%2F14651858.CD013022.pub2). [PMC](/source/PMC_(identifier)) [7045766](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045766). [PMID](/source/PMID_(identifier)) [32104908](https://pubmed.ncbi.nlm.nih.gov/32104908). 1. **[^](#cite_ref-95)** Yu CM, Wang L, Chau E, Chan RH, Kong SL, Tang MO, et al. (August 2005). ["Intrathoracic impedance monitoring in patients with heart failure: correlation with fluid status and feasibility of early warning preceding hospitalization"](https://doi.org/10.1161%2FCIRCULATIONAHA.104.492207). *Circulation*. **112** (6): 841–848. [doi](/source/Doi_(identifier)):[10.1161/CIRCULATIONAHA.104.492207](https://doi.org/10.1161%2FCIRCULATIONAHA.104.492207). [PMID](/source/PMID_(identifier)) [16061743](https://pubmed.ncbi.nlm.nih.gov/16061743). 1. **[^](#cite_ref-96)** Bashi N, Karunanithi M, Fatehi F, Ding H, Walters D (January 2017). ["Remote Monitoring of Patients With Heart Failure: An Overview of Systematic Reviews"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5291866). *Journal of Medical Internet Research*. **19** (1): e18. [doi](/source/Doi_(identifier)):[10.2196/jmir.6571](https://doi.org/10.2196%2Fjmir.6571). [PMC](/source/PMC_(identifier)) [5291866](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5291866). [PMID](/source/PMID_(identifier)) [28108430](https://pubmed.ncbi.nlm.nih.gov/28108430). 1. **[^](#cite_ref-97)** Inglis SC, Clark RA, Dierckx R, Prieto-Merino D, Cleland JG (October 2015). ["Structured telephone support or non-invasive telemonitoring for patients with heart failure"](https://dspace.flinders.edu.au/xmlui/bitstream/2328/35732/1/Inglis%20Structured%202015.pdf) (PDF). *The Cochrane Database of Systematic Reviews*. **2015** (10) CD007228. [doi](/source/Doi_(identifier)):[10.1002/14651858.CD007228.pub3](https://doi.org/10.1002%2F14651858.CD007228.pub3). [hdl](/source/Hdl_(identifier)):[2328/35732](https://hdl.handle.net/2328%2F35732). [PMC](/source/PMC_(identifier)) [8482064](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8482064). [PMID](/source/PMID_(identifier)) [26517969](https://pubmed.ncbi.nlm.nih.gov/26517969). [Archived](https://web.archive.org/web/20210828103110/https://dspace.flinders.edu.au/xmlui/bitstream/handle/2328/35732/Inglis%20Structured%202015.pdf;jsessionid=B2254F0FEBB8F13B06AFE621E018A88A?sequence=1) from the original on 28 August 2021. Retrieved 25 September 2019. 1. **[^](#cite_ref-hf-prevention_lifestyle_98-0)** ["Lifestyle Changes for Heart Failure"](http://www.heart.org/HEARTORG/Conditions/HeartFailure/PreventionTreatmentofHeartFailure/Lifestyle-Changes-for-Heart-Failure_UCM_306341_Article.jsp). [American Heart Association](/source/American_Heart_Association). [Archived](https://web.archive.org/web/20150503123439/http://www.heart.org/HEARTORG/Conditions/HeartFailure/PreventionTreatmentofHeartFailure/Lifestyle-Changes-for-Heart-Failure_UCM_306341_Article.jsp) from the original on 3 May 2015. 1. **[^](#cite_ref-99)** Mahtani KR, Heneghan C, Onakpoya I, Tierney S, Aronson JK, Roberts N, et al. (November 2018). ["Reduced Salt Intake for Heart Failure: A Systematic Review"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422065). *JAMA Internal Medicine*. **178** (12): 1693–1700. [doi](/source/Doi_(identifier)):[10.1001/jamainternmed.2018.4673](https://doi.org/10.1001%2Fjamainternmed.2018.4673). [PMC](/source/PMC_(identifier)) [6422065](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422065). [PMID](/source/PMID_(identifier)) [30398532](https://pubmed.ncbi.nlm.nih.gov/30398532). [S2CID](/source/S2CID_(identifier)) [53241717](https://api.semanticscholar.org/CorpusID:53241717). 1. **[^](#cite_ref-100)** Allida SM, Shehab S, Inglis SC, Davidson PM, Hayward CS, Newton PJ (April 2021). ["A RandomisEd ControLled TrIal of ChEwing Gum to RelieVE Thirst in Chronic Heart Failure (RELIEVE-CHF)"](https://www.heartlungcirc.org/article/S1443-9506(20)30480-7/fulltext). *Heart, Lung and Circulation*. **30** (4): 516–524. [doi](/source/Doi_(identifier)):[10.1016/j.hlc.2020.09.004](https://doi.org/10.1016%2Fj.hlc.2020.09.004). [hdl](/source/Hdl_(identifier)):[10453/146390](https://hdl.handle.net/10453%2F146390). [ISSN](/source/ISSN_(identifier)) [1443-9506](https://search.worldcat.org/issn/1443-9506). [PMID](/source/PMID_(identifier)) [33032897](https://pubmed.ncbi.nlm.nih.gov/33032897). [Archived](https://web.archive.org/web/20231115093428/https://www.heartlungcirc.org/article/S1443-9506(20)30480-7/fulltext) from the original on 15 November 2023. Retrieved 15 November 2023. 1. **[^](#cite_ref-101)** Amirova A, Fteropoulli T, Williams P, Haddad M (June 2021). ["Efficacy of interventions to increase physical activity for people with heart failure: a meta-analysis"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8191629). *Open Heart*. **8** (1) e001687. [doi](/source/Doi_(identifier)):[10.1136/openhrt-2021-001687](https://doi.org/10.1136%2Fopenhrt-2021-001687). [OCLC](/source/OCLC_(identifier)) [9066065537](https://search.worldcat.org/oclc/9066065537). [PMC](/source/PMC_(identifier)) [8191629](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8191629). [PMID](/source/PMID_(identifier)) [34108272](https://pubmed.ncbi.nlm.nih.gov/34108272). 1. **[^](#cite_ref-102)** Amirova A, Fteropoulli T, Williams P, Haddad M (June 2021). ["Efficacy of interventions to increase physical activity for people with heart failure: a meta-analysis"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8191629). *Open Heart*. **8** (1) e001687. [doi](/source/Doi_(identifier)):[10.1136/openhrt-2021-001687](https://doi.org/10.1136%2Fopenhrt-2021-001687). [PMC](/source/PMC_(identifier)) [8191629](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8191629). [PMID](/source/PMID_(identifier)) [34108272](https://pubmed.ncbi.nlm.nih.gov/34108272). 1. **[^](#cite_ref-Feltner_2014_103-0)** Feltner C, Jones CD, Cené CW, Zheng ZJ, Sueta CA, Coker-Schwimmer EJ, et al. (June 2014). "Transitional care interventions to prevent readmissions for persons with heart failure: a systematic review and meta-analysis". *Annals of Internal Medicine*. **160** (11): 774–84. [doi](/source/Doi_(identifier)):[10.7326/M14-0083](https://doi.org/10.7326%2FM14-0083). [hdl](/source/Hdl_(identifier)):[11250/2485759](https://hdl.handle.net/11250%2F2485759). [PMID](/source/PMID_(identifier)) [24862840](https://pubmed.ncbi.nlm.nih.gov/24862840). [S2CID](/source/S2CID_(identifier)) [262525144](https://api.semanticscholar.org/CorpusID:262525144). 1. **[^](#cite_ref-104)** Greene S, Khan M, et al. (March 2021). ["Quadruple Medical Therapy for Heart Failure"](https://doi.org/10.1016%2Fj.jacc.2021.02.006). *J Am Coll Cardiol*. **77** (11): 1408–1411. [doi](/source/Doi_(identifier)):[10.1016/j.jacc.2021.02.006](https://doi.org/10.1016%2Fj.jacc.2021.02.006). [PMID](/source/PMID_(identifier)) [33736822](https://pubmed.ncbi.nlm.nih.gov/33736822). [S2CID](/source/S2CID_(identifier)) [232299815](https://api.semanticscholar.org/CorpusID:232299815). 1. **[^](#cite_ref-105)** Straw S, McGinlay M, Witte KK (2021). ["Four pillars of heart failure: contemporary pharmacological therapy for heart failure with reduced ejection fraction"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7929859). *[Open Heart](/source/Open_Heart_(journal))*. **8** (1) e001585. [doi](/source/Doi_(identifier)):[10.1136/openhrt-2021-001585](https://doi.org/10.1136%2Fopenhrt-2021-001585). [PMC](/source/PMC_(identifier)) [7929859](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7929859). [PMID](/source/PMID_(identifier)) [33653703](https://pubmed.ncbi.nlm.nih.gov/33653703). 1. **[^](#cite_ref-106)** Goljan EF (2014). *Rapid Review Pathology* (4th ed.). Philadelphia, PA: Saunders/Elsevier. [ISBN](/source/ISBN_(identifier)) [978-0-323-08787-2](https://en.wikipedia.org/wiki/Special:BookSources/978-0-323-08787-2). 1. ^ [***a***](#cite_ref-NICECG108_107-0) [***b***](#cite_ref-NICECG108_107-1) [National Institute for Health and Clinical Excellence](/source/National_Institute_for_Health_and_Clinical_Excellence). *[Clinical guideline 108: Chronic heart failure – managements (ARBs) of chronic heart failure in adults in primary and secondary care](https://www.nice.org.uk/guidance/CG108)*. London, August 2010. 1. **[^](#cite_ref-108)** Kotecha D, Manzano L, Krum H, Rosano G, Holmes J, Altman DG, et al. (April 2016). ["Effect of age and sex on efficacy and tolerability of β blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4849174). *BMJ*. **353** i1855. [doi](/source/Doi_(identifier)):[10.1136/bmj.i1855](https://doi.org/10.1136%2Fbmj.i1855). [PMC](/source/PMC_(identifier)) [4849174](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4849174). [PMID](/source/PMID_(identifier)) [27098105](https://pubmed.ncbi.nlm.nih.gov/27098105). 1. **[^](#cite_ref-Kotecha_2014_109-0)** Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JG, et al. (December 2014). ["Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis"](http://pure-oai.bham.ac.uk/ws/files/21568198/Kotecha_et_al_Lancet_Efficacy_of_beta_blockers_The_Lancet_2014_Post_Print.pdf) (PDF). *Lancet*. **384** (9961): 2235–43. [doi](/source/Doi_(identifier)):[10.1016/S0140-6736(14)61373-8](https://doi.org/10.1016%2FS0140-6736%2814%2961373-8). [PMID](/source/PMID_(identifier)) [25193873](https://pubmed.ncbi.nlm.nih.gov/25193873). [S2CID](/source/S2CID_(identifier)) [25660815](https://api.semanticscholar.org/CorpusID:25660815). [Archived](https://web.archive.org/web/20200928221341/http://pure-oai.bham.ac.uk/ws/files/21568198/Kotecha_et_al_Lancet_Efficacy_of_beta_blockers_The_Lancet_2014_Post_Print.pdf) (PDF) from the original on 28 September 2020. Retrieved 27 May 2019. 1. **[^](#cite_ref-110)** Liu F, Chen Y, Feng X, Teng Z, Yuan Y, Bin J (5 March 2014). ["Effects of beta-blockers on heart failure with preserved ejection fraction: a meta-analysis"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3944014). *PLOS ONE*. **9** (3) e90555. [Bibcode](/source/Bibcode_(identifier)):[2014PLoSO...990555L](https://ui.adsabs.harvard.edu/abs/2014PLoSO...990555L). [doi](/source/Doi_(identifier)):[10.1371/journal.pone.0090555](https://doi.org/10.1371%2Fjournal.pone.0090555). [PMC](/source/PMC_(identifier)) [3944014](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3944014). [PMID](/source/PMID_(identifier)) [24599093](https://pubmed.ncbi.nlm.nih.gov/24599093). 1. ^ [***a***](#cite_ref-NatClinGuide_CHF_111-0) [***b***](#cite_ref-NatClinGuide_CHF_111-1) [***c***](#cite_ref-NatClinGuide_CHF_111-2) National Clinical Guideline Centre (UK) (August 2010). ["Chapter 5: Treating heart failure"](https://www.ncbi.nlm.nih.gov/books/NBK65330/). *Chronic Heart Failure: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care* (Partial Update [Internet]. ed.). London (UK): Royal College of Physicians. [Archived](https://web.archive.org/web/20170906120901/https://www.ncbi.nlm.nih.gov/books/NBK65330/) from the original on 6 September 2017. Retrieved 31 August 2017. 1. **[^](#cite_ref-113)** Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, et al. (September 2020). ["SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials"](https://doi.org/10.1016%2FS0140-6736%2820%2931824-9). *Lancet*. **396** (10254): 819–829. [doi](/source/Doi_(identifier)):[10.1016/S0140-6736(20)31824-9](https://doi.org/10.1016%2FS0140-6736%2820%2931824-9). [PMID](/source/PMID_(identifier)) [32877652](https://pubmed.ncbi.nlm.nih.gov/32877652). 1. **[^](#cite_ref-114)** ["Congestive Heart Failure"](https://www.lecturio.com/concepts/congestive-heart-failure/). *The Lecturio Medical Concept Library*. 7 August 2020. [Archived](https://web.archive.org/web/20210710035402/https://www.lecturio.com/concepts/congestive-heart-failure/) from the original on 10 July 2021. Retrieved 10 July 2021. 1. **[^](#cite_ref-115)** ["Digoxin"](https://www.drugs.com/monograph/digoxin.html). The American Society of Health-System Pharmacists. [Archived](https://web.archive.org/web/20161221004328/https://www.drugs.com/monograph/digoxin.html) from the original on 21 December 2016. Retrieved 8 December 2016. 1. **[^](#cite_ref-vonLueder_116-0)** von Lueder TG, Atar D, Krum H (October 2013). "Diuretic use in heart failure and outcomes". *Clinical Pharmacology and Therapeutics*. **94** (4): 490–8. [doi](/source/Doi_(identifier)):[10.1038/clpt.2013.140](https://doi.org/10.1038%2Fclpt.2013.140). [PMID](/source/PMID_(identifier)) [23852396](https://pubmed.ncbi.nlm.nih.gov/23852396). [S2CID](/source/S2CID_(identifier)) [7441258](https://api.semanticscholar.org/CorpusID:7441258). 1. **[^](#cite_ref-He2009_117-0)** He SW, Wang LX (2009). ["The impact of anemia on the prognosis of chronic heart failure: a meta-analysis and systemic review"](https://doi.org/10.1111%2Fj.1751-7133.2008.00030.x). *Congestive Heart Failure*. **15** (3): 123–30. [doi](/source/Doi_(identifier)):[10.1111/j.1751-7133.2008.00030.x](https://doi.org/10.1111%2Fj.1751-7133.2008.00030.x). [PMID](/source/PMID_(identifier)) [19522961](https://pubmed.ncbi.nlm.nih.gov/19522961). 1. **[^](#cite_ref-118)** Nunez-Gil MI, Peraira-Moral MJ (19 January 2012). ["Anaemia in heart failure: intravenous iron therapy"](https://web.archive.org/web/20130603124155/http://www.escardio.org/communities/councils/ccp/e-journal/volume10/Pages/anemia-in-heart-failure-intravenous-iron-therapy-Peraira-Moral-J-Roberto-Nunez-Gil-Ivan-J.aspx). *e-Journal of the ESC Council for Cardiology Practice*. **10** (16). Archived from [the original](http://www.escardio.org/communities/councils/ccp/e-journal/volume10/Pages/anemia-in-heart-failure-intravenous-iron-therapy-Peraira-Moral-J-Roberto-Nunez-Gil-Ivan-J.aspx) on 3 June 2013. Retrieved 3 October 2012. 1. ^ [***a***](#cite_ref-ACC2017_119-0) [***b***](#cite_ref-ACC2017_119-1) Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, et al. (August 2017). ["2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America"](https://doi.org/10.1161%2FCIR.0000000000000509). *Circulation*. **136** (6): e137–e161. [doi](/source/Doi_(identifier)):[10.1161/CIR.0000000000000509](https://doi.org/10.1161%2FCIR.0000000000000509). [PMID](/source/PMID_(identifier)) [28455343](https://pubmed.ncbi.nlm.nih.gov/28455343). 1. **[^](#cite_ref-Abraham_2013_120-0)** Abraham WT, Smith SA (February 2013). ["Devices in the management of advanced, chronic heart failure"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3753073). *Nature Reviews. Cardiology*. **10** (2): 98–110. [doi](/source/Doi_(identifier)):[10.1038/nrcardio.2012.178](https://doi.org/10.1038%2Fnrcardio.2012.178). [PMC](/source/PMC_(identifier)) [3753073](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3753073). [PMID](/source/PMID_(identifier)) [23229137](https://pubmed.ncbi.nlm.nih.gov/23229137). 1. **[^](#cite_ref-Giallauria_2014_121-0)** Giallauria F, Vigorito C, Piepoli MF, Stewart Coats AJ (August 2014). "Effects of cardiac contractility modulation by non-excitatory electrical stimulation on exercise capacity and quality of life: an individual patient's data meta-analysis of randomized controlled trials". *International Journal of Cardiology*. **175** (2): 352–7. [doi](/source/Doi_(identifier)):[10.1016/j.ijcard.2014.06.005](https://doi.org/10.1016%2Fj.ijcard.2014.06.005). [PMID](/source/PMID_(identifier)) [24975782](https://pubmed.ncbi.nlm.nih.gov/24975782). 1. **[^](#cite_ref-Borggrefe_2012_122-0)** Borggrefe M, Burkhoff D (July 2012). ["Clinical effects of cardiac contractility modulation (CCM) as a treatment for chronic heart failure"](https://doi.org/10.1093%2Feurjhf%2Fhfs078). *European Journal of Heart Failure*. **14** (7): 703–12. [doi](/source/Doi_(identifier)):[10.1093/eurjhf/hfs078](https://doi.org/10.1093%2Feurjhf%2Fhfs078). [PMID](/source/PMID_(identifier)) [22696514](https://pubmed.ncbi.nlm.nih.gov/22696514). [S2CID](/source/S2CID_(identifier)) [10484257](https://api.semanticscholar.org/CorpusID:10484257). 1. **[^](#cite_ref-Kuschyk_2015_123-0)** Kuschyk J, Roeger S, Schneider R, Streitner F, Stach K, Rudic B, et al. (March 2015). "Efficacy and survival in patients with cardiac contractility modulation: long-term single center experience in 81 patients". *International Journal of Cardiology*. **183** (183C): 76–81. [doi](/source/Doi_(identifier)):[10.1016/j.ijcard.2014.12.178](https://doi.org/10.1016%2Fj.ijcard.2014.12.178). [PMID](/source/PMID_(identifier)) [25662055](https://pubmed.ncbi.nlm.nih.gov/25662055). 1. **[^](#cite_ref-Kuschyk_2014a_124-0)** Kuschyk J (2014). ["Der Besondere Stellenwert der Kardialen Kontraktilitätsmodulation in der Devicetherapie"](http://cme.medlearning.de/herzmedizin/kardialen_kontraktilitaetsmodulation/cme.htm). *Herzmedizin*. [Archived](https://web.archive.org/web/20150705113329/http://cme.medlearning.de/herzmedizin/kardialen_kontraktilitaetsmodulation/cme.htm) from the original on 5 July 2015. Retrieved 6 June 2014. 1. **[^](#cite_ref-clinicaltrials_125-0)** Clinical trial number *[NCT01381172](https://www.clinicaltrials.gov/show/NCT01381172)* for "Evaluate Safety and Efficacy of the OPTIMIZER System in Subjects With Moderate-to-Severe Heart Failure: FIX-HF-5C (FIX-HF-5C)" at [ClinicalTrials.gov](/source/ClinicalTrials.gov) 1. **[^](#cite_ref-DAIC_2019_126-0)** ["FDA Approves Optimizer Smart System for Heart Failure Patients"](http://www.dicardiology.com/product/fda-approves-optimizer-smart-system-heart-failure-patients). *Diagnostic and Interventional Cardiology (DAIC)*. 21 March 2019. [Archived](https://web.archive.org/web/20230319124802/https://www.dicardiology.com/product/fda-approves-optimizer-smart-system-heart-failure-patients) from the original on 19 March 2023. Retrieved 25 June 2022. 1. **[^](#cite_ref-ACCFAHA2013_127-0)** Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al. (October 2013). ["2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines"](https://doi.org/10.1161%2FCIR.0b013e31829e8776). *Circulation*. **128** (16): e240–327. [doi](/source/Doi_(identifier)):[10.1161/CIR.0b013e31829e8776](https://doi.org/10.1161%2FCIR.0b013e31829e8776). [PMID](/source/PMID_(identifier)) [23741058](https://pubmed.ncbi.nlm.nih.gov/23741058). 1. **[^](#cite_ref-Ruschitzka_2013_128-0)** Ruschitzka F, Abraham WT, Singh JP, Bax JJ, Borer JS, Brugada J, et al. (October 2013). ["Cardiac-resynchronization therapy in heart failure with a narrow QRS complex"](https://www.zora.uzh.ch/id/eprint/84125/1/Ruschitzka_NEJMechoCRT.pdf) (PDF). *The New England Journal of Medicine*. **369** (15): 1395–405. [doi](/source/Doi_(identifier)):[10.1056/NEJMoa1306687](https://doi.org/10.1056%2FNEJMoa1306687). [PMID](/source/PMID_(identifier)) [23998714](https://pubmed.ncbi.nlm.nih.gov/23998714). [S2CID](/source/S2CID_(identifier)) [205095941](https://api.semanticscholar.org/CorpusID:205095941). [Archived](https://web.archive.org/web/20200728222046/https://www.zora.uzh.ch/id/eprint/84125/1/Ruschitzka_NEJMechoCRT.pdf) (PDF) from the original on 28 July 2020. Retrieved 24 November 2018. 1. **[^](#cite_ref-Carrel_2012_129-0)** Carrel T, Englberger L, Martinelli MV, Takala J, Boesch C, Sigurdadottir V, et al. (18 October 2012). ["Continuous flow left ventricular assist devices: a valid option for heart failure patients"](https://doi.org/10.4414%2Fsmw.2012.13701). *[Swiss Medical Weekly](/source/Swiss_Medical_Weekly)*. **142** (4142): w13701. [doi](/source/Doi_(identifier)):[10.4414/smw.2012.13701](https://doi.org/10.4414%2Fsmw.2012.13701). [PMID](/source/PMID_(identifier)) [23135811](https://pubmed.ncbi.nlm.nih.gov/23135811). 1. **[^](#cite_ref-130)** ["What Is Congestive Heart Failure?"](https://www.everydayhealth.com/congestive-heart-failure/guide/). *EverydayHealth.com*. Retrieved 26 December 2025. 1. **[^](#cite_ref-131)** Velazquez EJ, Lee KL, Jones RH, Al-Khalidi HR, Hill JA, Panza JA, et al. (21 April 2016). ["Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938005). *New England Journal of Medicine*. **374** (16): 1511–1520. [doi](/source/Doi_(identifier)):[10.1056/NEJMoa1602001](https://doi.org/10.1056%2FNEJMoa1602001). [ISSN](/source/ISSN_(identifier)) [0028-4793](https://search.worldcat.org/issn/0028-4793). [PMC](/source/PMC_(identifier)) [4938005](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938005). [PMID](/source/PMID_(identifier)) [27040723](https://pubmed.ncbi.nlm.nih.gov/27040723). 1. **[^](#cite_ref-Lindenfeld_2004_132-0)** Lindenfeld J, Miller GG, Shakar SF, Zolty R, Lowes BD, Wolfel EE, et al. (December 2004). ["Drug therapy in the heart transplant recipient: part I: cardiac rejection and immunosuppressive drugs"](https://doi.org/10.1161%2F01.cir.0000149745.83186.89). *Circulation*. **110** (24): 3734–3740. [doi](/source/Doi_(identifier)):[10.1161/01.cir.0000149745.83186.89](https://doi.org/10.1161%2F01.cir.0000149745.83186.89). [PMID](/source/PMID_(identifier)) [15596559](https://pubmed.ncbi.nlm.nih.gov/15596559). 1. ^ [***a***](#cite_ref-Kavalieratos2017_133-0) [***b***](#cite_ref-Kavalieratos2017_133-1) Kavalieratos D, Gelfman LP, Tycon LE, Riegel B, Bekelman DB, Ikejiani DZ, et al. (October 2017). ["Palliative Care in Heart Failure: Rationale, Evidence, and Future Priorities"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731659). *Journal of the American College of Cardiology*. **70** (15): 1919–1930. [doi](/source/Doi_(identifier)):[10.1016/j.jacc.2017.08.036](https://doi.org/10.1016%2Fj.jacc.2017.08.036). [PMC](/source/PMC_(identifier)) [5731659](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731659). [PMID](/source/PMID_(identifier)) [28982506](https://pubmed.ncbi.nlm.nih.gov/28982506). 1. ^ [***a***](#cite_ref-AHAJournPallaiative_134-0) [***b***](#cite_ref-AHAJournPallaiative_134-1) Adler ED, Goldfinger JZ, Kalman J, Park ME, Meier DE (December 2009). ["Palliative care in the treatment of advanced heart failure"](https://doi.org/10.1161%2FCIRCULATIONAHA.109.869123). *Circulation*. **120** (25): 2597–606. [doi](/source/Doi_(identifier)):[10.1161/CIRCULATIONAHA.109.869123](https://doi.org/10.1161%2FCIRCULATIONAHA.109.869123). [PMID](/source/PMID_(identifier)) [20026792](https://pubmed.ncbi.nlm.nih.gov/20026792). 1. **[^](#cite_ref-Kavalieratos2016_135-0)** Kavalieratos D, Corbelli J, Zhang D, Dionne-Odom JN, Ernecoff NC, Hanmer J, et al. (November 2016). ["Association Between Palliative Care and Patient and Caregiver Outcomes: A Systematic Review and Meta-analysis"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226373). *JAMA*. **316** (20): 2104–2114. [doi](/source/Doi_(identifier)):[10.1001/jama.2016.16840](https://doi.org/10.1001%2Fjama.2016.16840). [PMC](/source/PMC_(identifier)) [5226373](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226373). [PMID](/source/PMID_(identifier)) [27893131](https://pubmed.ncbi.nlm.nih.gov/27893131). 1. **[^](#cite_ref-pmid17449141_136-0)** Auble TE, Hsieh M, McCausland JB, Yealy DM (August 2007). "Comparison of four clinical prediction rules for estimating risk in heart failure". *Annals of Emergency Medicine*. **50** (2): 127–35, 135.e1–2. [doi](/source/Doi_(identifier)):[10.1016/j.annemergmed.2007.02.017](https://doi.org/10.1016%2Fj.annemergmed.2007.02.017). [PMID](/source/PMID_(identifier)) [17449141](https://pubmed.ncbi.nlm.nih.gov/17449141). 1. **[^](#cite_ref-137)** Mehra MR, Kobashigawa J, Starling R, Russell S, Uber PA, Parameshwar J, et al. (September 2006). "Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates – 2006". *The Journal of Heart and Lung Transplantation*. **25** (9): 1024–42. [doi](/source/Doi_(identifier)):[10.1016/j.healun.2006.06.008](https://doi.org/10.1016%2Fj.healun.2006.06.008). [PMID](/source/PMID_(identifier)) [16962464](https://pubmed.ncbi.nlm.nih.gov/16962464). 1. **[^](#cite_ref-pmid11847161_138-0)** Juenger J, Schellberg D, Kraemer S, Haunstetter A, Zugck C, Herzog W, et al. (March 2002). ["Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1767036). *Heart*. **87** (3): 235–241. [doi](/source/Doi_(identifier)):[10.1136/heart.87.3.235](https://doi.org/10.1136%2Fheart.87.3.235). [PMC](/source/PMC_(identifier)) [1767036](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1767036). [PMID](/source/PMID_(identifier)) [11847161](https://pubmed.ncbi.nlm.nih.gov/11847161). 1. **[^](#cite_ref-pmid12445536_139-0)** Hobbs FD, Kenkre JE, Roalfe AK, Davis RC, Hare R, Davies MK (December 2002). "Impact of heart failure and left ventricular systolic dysfunction on quality of life: a cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population". *European Heart Journal*. **23** (23): 1867–1876. [doi](/source/Doi_(identifier)):[10.1053/euhj.2002.3255](https://doi.org/10.1053%2Feuhj.2002.3255). [PMID](/source/PMID_(identifier)) [12445536](https://pubmed.ncbi.nlm.nih.gov/12445536). 1. **[^](#cite_ref-neubauer-2007_140-0)** Neubauer S (March 2007). "The failing heart--an engine out of fuel". *The New England Journal of Medicine*. **356** (11): 1140–1151. [doi](/source/Doi_(identifier)):[10.1056/NEJMra063052](https://doi.org/10.1056%2FNEJMra063052). [PMID](/source/PMID_(identifier)) [17360992](https://pubmed.ncbi.nlm.nih.gov/17360992). [S2CID](/source/S2CID_(identifier)) [1481349](https://api.semanticscholar.org/CorpusID:1481349). 1. **[^](#cite_ref-WITT2007_141-0)** Witt BJ, Gami AS, Ballman KV, Brown RD, Meverden RA, Jacobsen SJ, et al. (August 2007). "The incidence of ischemic stroke in chronic heart failure: a meta-analysis". *Journal of Cardiac Failure*. **13** (6): 489–96. [doi](/source/Doi_(identifier)):[10.1016/j.cardfail.2007.01.009](https://doi.org/10.1016%2Fj.cardfail.2007.01.009). [PMID](/source/PMID_(identifier)) [17675064](https://pubmed.ncbi.nlm.nih.gov/17675064). 1. **[^](#cite_ref-pmid35078371_142-0)** Tsao CW, et al. (February 2022). ["Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association"](https://doi.org/10.1161%2FCIR.0000000000001052). *Circulation*. **145** (8): e153–e639. [Bibcode](/source/Bibcode_(identifier)):[2022Circu.14501052T](https://ui.adsabs.harvard.edu/abs/2022Circu.14501052T). [doi](/source/Doi_(identifier)):[10.1161/CIR.0000000000001052](https://doi.org/10.1161%2FCIR.0000000000001052). [PMID](/source/PMID_(identifier)) [35078371](https://pubmed.ncbi.nlm.nih.gov/35078371). 1. **[^](#cite_ref-Harrisons_143-0)** Mann DL, Chakinala M (2012). ["Chapter 234. Heart Failure and Cor Pulmonale"](http://www.accessmedicine.com/content.aspx?aID=9126630). *Harrison's principles of internal medicine: Chapter 234. Heart Failure and Cor Pulmonale* (18th ed.). New York: McGraw-Hill. [ISBN](/source/ISBN_(identifier)) [978-0-07-174889-6](https://en.wikipedia.org/wiki/Special:BookSources/978-0-07-174889-6). [Archived](https://web.archive.org/web/20131014173522/http://www.accessmedicine.com/content.aspx?aID=9126630) from the original on 14 October 2013. 1. **[^](#cite_ref-144)** Massie BM (2011). "Chapter 58: Heart Failure: Pathophysiology and Diagnosis". In Goldman L, Schafer AI (eds.). *Goldman's Cecil Medicine* (24th ed.). Philadelphia: Elsevier Saunders. pp. 295–302. [ISBN](/source/ISBN_(identifier)) [978-1-4377-2788-3](https://en.wikipedia.org/wiki/Special:BookSources/978-1-4377-2788-3). 1. **[^](#cite_ref-145)** McMurray JJ, Pfeffer MA (2011). "Chapter 59: Heart Failure: Management and Diagnosis". In Goldman L, Schafer AI (eds.). *Goldman's Cecil Medicine* (24th ed.). Philadelphia: Elsevier Saunders. pp. 303–317. [ISBN](/source/ISBN_(identifier)) [978-1-4377-2788-3](https://en.wikipedia.org/wiki/Special:BookSources/978-1-4377-2788-3). 1. **[^](#cite_ref-146)** Krumholz HM, Chen YT, Wang Y, Vaccarino V, Radford MJ, Horwitz RI (January 2000). "Predictors of readmission among elderly survivors of admission with heart failure". *American Heart Journal*. **139** (1 Pt 1): 72–7. [doi](/source/Doi_(identifier)):[10.1016/S0002-8703(00)90311-9](https://doi.org/10.1016%2FS0002-8703%2800%2990311-9). [PMID](/source/PMID_(identifier)) [10618565](https://pubmed.ncbi.nlm.nih.gov/10618565). 1. **[^](#cite_ref-EpidemRiskProfile_147-0)** Bui AL, Horwich TB, Fonarow GC (January 2011). ["Epidemiology and risk profile of heart failure"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033496). *Nature Reviews. Cardiology*. **8** (1): 30–41. [doi](/source/Doi_(identifier)):[10.1038/nrcardio.2010.165](https://doi.org/10.1038%2Fnrcardio.2010.165). [PMC](/source/PMC_(identifier)) [3033496](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033496). [PMID](/source/PMID_(identifier)) [21060326](https://pubmed.ncbi.nlm.nih.gov/21060326). 1. **[^](#cite_ref-148)** Pfuntner A, Wier LM, Stocks C (September 2013). ["Most Frequent Conditions in U.S. Hospitals, 2011"](https://www.hcup-us.ahrq.gov/reports/statbriefs/sb162.jsp). *HCUP Statistical Brief* (162). Rockville, MD: Agency for Healthcare Research and Quality. [Archived](https://web.archive.org/web/20160304032807/http://www.hcup-us.ahrq.gov/reports/statbriefs/sb162.jsp) from the original on 4 March 2016. Retrieved 9 February 2016. 1. **[^](#cite_ref-149)** Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. (January 2013). ["Heart disease and stroke statistics – 2013 update: a report from the American Heart Association"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408511). *Circulation*. **127** (1): e6–e245. [Bibcode](/source/Bibcode_(identifier)):[2013Circu.127124adG](https://ui.adsabs.harvard.edu/abs/2013Circu.127124adG). [doi](/source/Doi_(identifier)):[10.1161/cir.0b013e31828124ad](https://doi.org/10.1161%2Fcir.0b013e31828124ad). [PMC](/source/PMC_(identifier)) [5408511](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408511). [PMID](/source/PMID_(identifier)) [23239837](https://pubmed.ncbi.nlm.nih.gov/23239837). 1. **[^](#cite_ref-150)** ["Heart disease facts"](https://www.cdc.gov/heartdisease/facts.htm). US Centers for Disease Control and Prevention. 15 May 2023. [Archived](https://web.archive.org/web/20210124222820/https://www.cdc.gov/heartdisease/facts.htm) from the original on 24 January 2021. Retrieved 8 July 2023. 1. **[^](#cite_ref-151)** Elixhauser A, Steiner C. *Readmissions to U.S. Hospitals by Diagnosis, 2010.* HCUP Statistical Brief #153. Agency for Healthcare Research and Quality. April 2013. ["Statistical Brief #153"](https://hcup-us.ahrq.gov/reports/statbriefs/sb153.jsp). [Archived](https://web.archive.org/web/20150418001040/http://hcup-us.ahrq.gov/reports/statbriefs/sb153.jsp) from the original on 18 April 2015. Retrieved 8 May 2013. 1. **[^](#cite_ref-152)** Hines AL, Barrett ML, Jiang HJ, Steiner CA (April 2014). ["Conditions With the Largest Number of Adult Hospital Readmissions by Payer, 2011"](https://hcup-us.ahrq.gov/reports/statbriefs/sb172-Conditions-Readmissions-Payer.jsp). *HCUP Statistical Brief* (172). Rockville, MD: Agency for Healthcare Research and Quality. [PMID](/source/PMID_(identifier)) [24901179](https://pubmed.ncbi.nlm.nih.gov/24901179). [Archived](https://web.archive.org/web/20160304052719/http://hcup-us.ahrq.gov/reports/statbriefs/sb172-Conditions-Readmissions-Payer.jsp) from the original on 4 March 2016. 1. ^ [***a***](#cite_ref-Incidence_2017_153-0) [***b***](#cite_ref-Incidence_2017_153-1) [***c***](#cite_ref-Incidence_2017_153-2) Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP, et al. (February 2018). ["Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814791). *Lancet*. **391** (10120): 572–580. [doi](/source/Doi_(identifier)):[10.1016/S0140-6736(17)32520-5](https://doi.org/10.1016%2FS0140-6736%2817%2932520-5). [PMC](/source/PMC_(identifier)) [5814791](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814791). [PMID](/source/PMID_(identifier)) [29174292](https://pubmed.ncbi.nlm.nih.gov/29174292). 1. **[^](#cite_ref-154)** Sanderson JE, Tse Tf (June 2003). ["Heart failure: a global disease requiring a global response"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1767689). *Heart (British Cardiac Society)*. **89** (6): 585–586. [doi](/source/Doi_(identifier)):[10.1136/heart.89.6.585](https://doi.org/10.1136%2Fheart.89.6.585). [ISSN](/source/ISSN_(identifier)) [1468-201X](https://search.worldcat.org/issn/1468-201X). [PMC](/source/PMC_(identifier)) [1767689](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1767689). [PMID](/source/PMID_(identifier)) [12748201](https://pubmed.ncbi.nlm.nih.gov/12748201). 1. ^ [***a***](#cite_ref-Stromberg_155-0) [***b***](#cite_ref-Stromberg_155-1) Strömberg A, Mårtensson J (April 2003). ["Gender differences in patients with heart failure"](https://doi.org/10.1016%2FS1474-5151%2803%2900002-1). *European Journal of Cardiovascular Nursing*. **2** (1): 7–18. [doi](/source/Doi_(identifier)):[10.1016/S1474-5151(03)00002-1](https://doi.org/10.1016%2FS1474-5151%2803%2900002-1). [PMID](/source/PMID_(identifier)) [14622644](https://pubmed.ncbi.nlm.nih.gov/14622644). [S2CID](/source/S2CID_(identifier)) [41171172](https://api.semanticscholar.org/CorpusID:41171172). 1. **[^](#cite_ref-156)** Solanki P (2015). "Heart Failure in South Asian Population". *Management of Heart Failure*. pp. 305–317. [doi](/source/Doi_(identifier)):[10.1007/978-1-4471-6657-3_16](https://doi.org/10.1007%2F978-1-4471-6657-3_16). [ISBN](/source/ISBN_(identifier)) [978-1-4471-6656-6](https://en.wikipedia.org/wiki/Special:BookSources/978-1-4471-6656-6). 1. **[^](#cite_ref-157)** Reyes EB, Ha JW, Firdaus I, Ghazi AM, Phrommintikul A, Sim D, et al. (November 2016). ["Heart failure across Asia: Same healthcare burden but differences in organization of care"](https://doi.org/10.1016%2Fj.ijcard.2016.07.256). *International Journal of Cardiology*. **223**: 163–167. [doi](/source/Doi_(identifier)):[10.1016/j.ijcard.2016.07.256](https://doi.org/10.1016%2Fj.ijcard.2016.07.256). [hdl](/source/Hdl_(identifier)):[10722/232019](https://hdl.handle.net/10722%2F232019). [PMID](/source/PMID_(identifier)) [27541646](https://pubmed.ncbi.nlm.nih.gov/27541646). 1. **[^](#cite_ref-pmid16911907_158-0)** Saba MM, Ventura HO, Saleh M, Mehra MR (2006). "Ancient Egyptian medicine and the concept of heart failure". *J Card Fail*. **12** (6): 416–21. [doi](/source/Doi_(identifier)):[10.1016/j.cardfail.2006.03.001](https://doi.org/10.1016%2Fj.cardfail.2006.03.001). [PMID](/source/PMID_(identifier)) [16911907](https://pubmed.ncbi.nlm.nih.gov/16911907). 1. ^ [***a***](#cite_ref-pmid8502981_159-0) [***b***](#cite_ref-pmid8502981_159-1) [***c***](#cite_ref-pmid8502981_159-2) Nolan J (April 1993). "A historical review of heart failure". *Scottish Medical Journal*. **38** (2): 53–57. [doi](/source/Doi_(identifier)):[10.1177/003693309303800208](https://doi.org/10.1177%2F003693309303800208). [PMID](/source/PMID_(identifier)) [8502981](https://pubmed.ncbi.nlm.nih.gov/8502981). [S2CID](/source/S2CID_(identifier)) [5216806](https://api.semanticscholar.org/CorpusID:5216806). 1. ^ [***a***](#cite_ref-pmid15685783_160-0) [***b***](#cite_ref-pmid15685783_160-1) Norn S, Kruse PR (2004). "[Cardiac glycosides: From ancient history through Withering's foxglove to endogeneous cardiac glycosides]". *Dansk Medicinhistorisk Arbog*: 119–132. [PMID](/source/PMID_(identifier)) [15685783](https://pubmed.ncbi.nlm.nih.gov/15685783). 1. ^ [***a***](#cite_ref-pmid31620262_161-0) [***b***](#cite_ref-pmid31620262_161-1) Hajar R (2019). ["Congestive Heart Failure: A History"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6791096). *Heart Views*. **20** (3): 129–132. [doi](/source/Doi_(identifier)):[10.4103/HEARTVIEWS.HEARTVIEWS_77_19](https://doi.org/10.4103%2FHEARTVIEWS.HEARTVIEWS_77_19). [PMC](/source/PMC_(identifier)) [6791096](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6791096). [PMID](/source/PMID_(identifier)) [31620262](https://pubmed.ncbi.nlm.nih.gov/31620262). 1. ^ [***a***](#cite_ref-pmid31980269_162-0) [***b***](#cite_ref-pmid31980269_162-1) Bestetti RB, Cardinalli-Neto A, Couto LB (April 2020). "The history of the evolution of the knowledge about the diagnosis and the pathogenetic aspects of heart failure: From the Egyptians to James Mackenzie". *International Journal of Cardiology*. **304**: 109–115. [doi](/source/Doi_(identifier)):[10.1016/j.ijcard.2019.12.050](https://doi.org/10.1016%2Fj.ijcard.2019.12.050). [PMID](/source/PMID_(identifier)) [31980269](https://pubmed.ncbi.nlm.nih.gov/31980269). [S2CID](/source/S2CID_(identifier)) [210890303](https://api.semanticscholar.org/CorpusID:210890303). 1. **[^](#cite_ref-pmid4896254_163-0)** Jarcho S (August 1969). ["An Eighteenth Century treatise on dropsy of the chest (Buchner, 1742)"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1750442). *Bulletin of the New York Academy of Medicine*. **45** (8): 799–806. [PMC](/source/PMC_(identifier)) [1750442](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1750442). [PMID](/source/PMID_(identifier)) [4896254](https://pubmed.ncbi.nlm.nih.gov/4896254). 1. **[^](#cite_ref-pmid9185118_164-0)** Eknoyan G (June 1997). "A history of edema and its management". *Kidney International. Supplement*. **59**: S118–26. [PMID](/source/PMID_(identifier)) [9185118](https://pubmed.ncbi.nlm.nih.gov/9185118). 1. ^ [***a***](#cite_ref-pmid13437417_165-0) [***b***](#cite_ref-pmid13437417_165-1) [***c***](#cite_ref-pmid13437417_165-2) White PD (June 1957). ["The evolution of our knowledge about the heart and its diseases since 1628"](https://doi.org/10.1161%2F01.cir.15.6.915). *Circulation*. **15** (6): 915–23. [doi](/source/Doi_(identifier)):[10.1161/01.cir.15.6.915](https://doi.org/10.1161%2F01.cir.15.6.915). [PMID](/source/PMID_(identifier)) [13437417](https://pubmed.ncbi.nlm.nih.gov/13437417). 1. **[^](#cite_ref-pmid28510104_166-0)** Sequeira V, van der Velden J (December 2015). ["Historical perspective on heart function: the Frank–Starling Law"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418489). *Biophysical Reviews*. **7** (4): 421–447. [doi](/source/Doi_(identifier)):[10.1007/s12551-015-0184-4](https://doi.org/10.1007%2Fs12551-015-0184-4). [PMC](/source/PMC_(identifier)) [5418489](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418489). [PMID](/source/PMID_(identifier)) [28510104](https://pubmed.ncbi.nlm.nih.gov/28510104). 1. ^ [***a***](#cite_ref-pmid15880332_167-0) [***b***](#cite_ref-pmid15880332_167-1) Ventura HO, Mehra MR (May 2005). "Bloodletting as a cure for dropsy: heart failure down the ages". *Journal of Cardiac Failure*. **11** (4): 247–52. [doi](/source/Doi_(identifier)):[10.1016/j.cardfail.2004.10.003](https://doi.org/10.1016%2Fj.cardfail.2004.10.003). [PMID](/source/PMID_(identifier)) [15880332](https://pubmed.ncbi.nlm.nih.gov/15880332). 1. **[^](#cite_ref-pmid8672051_168-0)** Eknoyan G (July 1996). ["Historical note. On the contributions of Paracelsus to nephrology"](https://doi.org/10.1093%2Fndt%2F11.7.1388). *Nephrology, Dialysis, Transplantation*. **11** (7): 1388–1394. [doi](/source/Doi_(identifier)):[10.1093/ndt/11.7.1388](https://doi.org/10.1093%2Fndt%2F11.7.1388). [PMID](/source/PMID_(identifier)) [8672051](https://pubmed.ncbi.nlm.nih.gov/8672051). 1. ^ [***a***](#cite_ref-Ventura_169-0) [***b***](#cite_ref-Ventura_169-1) [***c***](#cite_ref-Ventura_169-2) [***d***](#cite_ref-Ventura_169-3) Ventura HO. ["A Glimpse of Yesterday: Treatment of "Dropsy" (Slides with Transcript)"](https://www.medscape.org/viewarticle/557959). *Medscape*. [Archived](https://web.archive.org/web/20170930071331/http://www.medscape.org/viewarticle/557959) from the original on 30 September 2017. Retrieved 26 February 2021. 1. **[^](#cite_ref-pmid16760707_170-0)** Ventura HO (2006). ["History of heart failure"](https://doi.org/10.1111%2Fj.1527-5299.2005.04956.x). *Congestive Heart Failure*. **12** (3): 178. [doi](/source/Doi_(identifier)):[10.1111/j.1527-5299.2005.04956.x](https://doi.org/10.1111%2Fj.1527-5299.2005.04956.x). [PMID](/source/PMID_(identifier)) [16760707](https://pubmed.ncbi.nlm.nih.gov/16760707). 1. **[^](#cite_ref-pmid22528171_171-0)** Lüderitz B (May 2011). "[On the history of heart failure]". *Clinical Research in Cardiology Supplements*. **6**: 2–5. [doi](/source/Doi_(identifier)):[10.1007/s11789-011-0026-2](https://doi.org/10.1007%2Fs11789-011-0026-2). [PMID](/source/PMID_(identifier)) [22528171](https://pubmed.ncbi.nlm.nih.gov/22528171). [S2CID](/source/S2CID_(identifier)) [116245349](https://api.semanticscholar.org/CorpusID:116245349). 1. **[^](#cite_ref-pmid18610472_172-0)** Swedberg K (June 1998). ["History of Beta blockers in congestive heart failure"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1766483). *Heart*. **79** (Suppl 2): S29-30. [doi](/source/Doi_(identifier)):[10.1136/hrt.79.2008.29s](https://doi.org/10.1136%2Fhrt.79.2008.29s). [PMC](/source/PMC_(identifier)) [1766483](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1766483). [PMID](/source/PMID_(identifier)) [18610472](https://pubmed.ncbi.nlm.nih.gov/18610472). 1. **[^](#cite_ref-173)** Torio CM, Andrews RM. National Inpatient Hospital Costs: The Most Expensive Conditions by Payer, 2011. HCUP Statistical Brief #160. Agency for Healthcare Research and Quality, Rockville, MD. August 2013. ["Statistical Brief #160"](https://hcup-us.ahrq.gov/reports/statbriefs/sb160.jsp). [Archived](https://web.archive.org/web/20170314171958/https://www.hcup-us.ahrq.gov/reports/statbriefs/sb160.jsp) from the original on 14 March 2017. Retrieved 1 May 2017. 1. **[^](#cite_ref-pmid12034163_174-0)** Stewart S, Jenkins A, Buchan S, McGuire A, Capewell S, McMurray JJ (June 2002). "The current cost of heart failure to the National Health Service in the UK". *European Journal of Heart Failure*. **4** (3): 361–71. [doi](/source/Doi_(identifier)):[10.1016/S1388-9842(01)00198-2](https://doi.org/10.1016%2FS1388-9842%2801%2900198-2). [PMID](/source/PMID_(identifier)) [12034163](https://pubmed.ncbi.nlm.nih.gov/12034163). [S2CID](/source/S2CID_(identifier)) [12765307](https://api.semanticscholar.org/CorpusID:12765307). 1. **[^](#cite_ref-pmid18086926_175-0)** Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, et al. (January 2008). ["Heart disease and stroke statistics – 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee"](https://doi.org/10.1161%2FCIRCULATIONAHA.107.187998). *Circulation*. **117** (4): e25–146. [doi](/source/Doi_(identifier)):[10.1161/CIRCULATIONAHA.107.187998](https://doi.org/10.1161%2FCIRCULATIONAHA.107.187998). [PMID](/source/PMID_(identifier)) [18086926](https://pubmed.ncbi.nlm.nih.gov/18086926). 1. ^ [***a***](#cite_ref-ReferenceB_176-0) [***b***](#cite_ref-ReferenceB_176-1) Fisher SA, Doree C, Mathur A, Taggart DP, Martin-Rendon E (December 2016). ["Stem cell therapy for chronic ischaemic heart disease and congestive heart failure"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463978). *The Cochrane Database of Systematic Reviews*. **2016** (12) CD007888. [doi](/source/Doi_(identifier)):[10.1002/14651858.CD007888.pub3](https://doi.org/10.1002%2F14651858.CD007888.pub3). [PMC](/source/PMC_(identifier)) [6463978](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463978). [PMID](/source/PMID_(identifier)) [28012165](https://pubmed.ncbi.nlm.nih.gov/28012165). 1. **[^](#cite_ref-177)** Nowbar AN, Mielewczik M, Karavassilis M, Dehbi HM, Shun-Shin MJ, Jones S, et al. (April 2014). ["Discrepancies in autologous bone marrow stem cell trials and enhancement of ejection fraction (DAMASCENE): weighted regression and meta-analysis"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4002982). *BMJ*. **348** g2688. [doi](/source/Doi_(identifier)):[10.1136/bmj.g2688](https://doi.org/10.1136%2Fbmj.g2688). [PMC](/source/PMC_(identifier)) [4002982](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4002982). [PMID](/source/PMID_(identifier)) [24778175](https://pubmed.ncbi.nlm.nih.gov/24778175). 1. ^ [***a***](#cite_ref-Papait2020_178-0) [***b***](#cite_ref-Papait2020_178-1) Papait R, Serio S, Condorelli G (October 2020). "Role of the Epigenome in Heart Failure". *Physiol Rev*. **100** (4): 1753–1777. [doi](/source/Doi_(identifier)):[10.1152/physrev.00037.2019](https://doi.org/10.1152%2Fphysrev.00037.2019). [PMID](/source/PMID_(identifier)) [32326823](https://pubmed.ncbi.nlm.nih.gov/32326823). 1. ^ [***a***](#cite_ref-Zhao2022_179-0) [***b***](#cite_ref-Zhao2022_179-1) Zhao K, Mao Y, Li Y, Yang C, Wang K, Zhang J (2022). ["The roles and mechanisms of epigenetic regulation in pathological myocardial remodeling"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458904). *Front Cardiovasc Med*. **9** 952949. [doi](/source/Doi_(identifier)):[10.3389/fcvm.2022.952949](https://doi.org/10.3389%2Ffcvm.2022.952949). [PMC](/source/PMC_(identifier)) [9458904](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458904). [PMID](/source/PMID_(identifier)) [36093141](https://pubmed.ncbi.nlm.nih.gov/36093141). ## External links Wikimedia Commons has media related to [Heart failure](https://commons.wikimedia.org/wiki/Category:Heart_failure). - [Medicine portal](https://en.wikipedia.org/wiki/Portal:Medicine) - [Heart failure](http://www.heart.org/HEARTORG/Conditions/HeartFailure/Heart-Failure_UCM_002019_SubHomePage.jsp), American Heart Association – information and resources for treating and living with heart failure - [Heart Failure Matters](http://www.heartfailurematters.org) – patient information website of the Heart Failure Association of the European Society of Cardiology - [Heart failure in children](https://web.archive.org/web/20111110001802/https://www.gosh.nhs.uk/medical-conditions/search-for-medical-conditions/heart-failure-severe/) by Great Ormond Street Hospital, London, UK - ["Heart Failure"](https://medlineplus.gov/heartfailure.html). *MedlinePlus*. U.S. National Library of Medicine. - [2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure](https://www.acc.org/guidelines/hubs/heart-failure) - Guideline Hub at [American College of Cardiology](/source/American_College_of_Cardiology), jointly with the [American Heart Association](/source/American_Heart_Association) and the [Heart Failure Society of America](/source/Heart_Failure_Society_of_America). JACC article link, quick references, slides, perspectives, education, apps and tools, and patient resources. April, 2022 - [2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure](https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Acute-and-Chronic-Heart-Failure) – [European Society of Cardiology](/source/European_Society_of_Cardiology) resource webpage with links to Full text and related materials, scientific presentation at ESC Congress 2021, news article, TV interview, app, slide set, and ESC Pocket Guidelines; plus previous versions. August, 2021. Classification D ICD-11: BD10-BD1Z, KB40 ICD-10: I50, I11.0, I13.0, I13.2, I97.1, P29.0 ICD-9-CM: 428.0 MeSH: D006333 DiseasesDB: 16209 External resources MedlinePlus: 000158 Patient UK: Heart failure v t e Cardiovascular disease (heart) Ischemia Coronary disease Coronary artery disease (CAD) Coronary artery aneurysm Spontaneous coronary artery dissection (SCAD) Coronary thrombosis Coronary vasospasm Myocardial bridge Active ischemia Angina pectoris Prinzmetal's angina Stable angina Acute coronary syndrome Myocardial infarction Unstable angina Sequelae hours Hibernating myocardium Myocardial stunning days Myocardial rupture weeks Ventricular aneurysm Dressler syndrome Layers Pericardium Pericarditis Acute Chronic / Constrictive Pericardial effusion Cardiac tamponade Hemopericardium Myocardium Myocarditis Chagas disease Cardiomyopathy Dilated Alcoholic Hypertrophic Tachycardia-induced Restrictive Loeffler endocarditis Cardiac amyloidosis Endocardial fibroelastosis Viral Arrhythmogenic right ventricular dysplasia Endocardium / valves Endocarditis infective endocarditis Subacute bacterial endocarditis non-infective endocarditis Libman–Sacks endocarditis Nonbacterial thrombotic endocarditis Valves mitral prolapse stenosis regurgitation aortic stenosis regurgitation tricuspid stenosis regurgitation pulmonary stenosis regurgitation Conduction / arrhythmia Bradycardia Sinus bradycardia Sick sinus syndrome Heart block: Sinoatrial AV 1° 2° 3° Intraventricular Bundle branch block Right Left Left anterior fascicle Left posterior fascicle Bifascicular Trifascicular Adams–Stokes syndrome Tachycardia (paroxysmal and sinus) Supraventricular Atrial Multifocal Junctional AV nodal reentrant Junctional ectopic Ventricular Accelerated idioventricular rhythm Catecholaminergic polymorphic Torsades de pointes Premature contraction Atrial Junctional Ventricular Pre-excitation syndrome Lown–Ganong–Levine Wolff–Parkinson–White Flutter / fibrillation Atrial flutter Ventricular flutter Atrial fibrillation Familial Ventricular fibrillation Pacemaker Ectopic pacemaker / Ectopic beat Multifocal atrial tachycardia Pacemaker syndrome Parasystole Wandering atrial pacemaker Long QT syndrome Andersen–Tawil Jervell and Lange-Nielsen Romano–Ward Cardiac arrest Sudden cardiac death Asystole Pulseless electrical activity Sinoatrial arrest Other / ungrouped hexaxial reference system Right axis deviation Left axis deviation QT Short QT syndrome T T wave alternans ST J wave ST elevation ST depression Strain pattern Cardiomegaly Ventricular hypertrophy Left Right Pulmonary Atrial enlargement Left Right Athletic heart syndrome Other Cardiac fibrosis Heart failure Diastolic heart failure Cardiac asthma Rheumatic fever Obstructive shock v t e Organ failure General Heart failure Respiratory failure Liver failure Acute Chronic Renal failure Acute Chronic Encephalopathy Multiple Multiple organ dysfunction syndrome Authority control databases International GND National United States France BnF data Japan Czech Republic Latvia Israel Other Yale LUX --- Adapted from the Wikipedia article [Heart failure](https://en.wikipedia.org/wiki/Heart_failure) by Wikipedia contributors ([contributor history](https://en.wikipedia.org/wiki/Heart_failure?action=history)). Available under [Creative Commons Attribution-ShareAlike 4.0 International](https://creativecommons.org/licenses/by-sa/4.0/). Changes may have been made.